go 6976 profile

ID Source	ID
PubMed CID	3501
CHEMBL ID	302449
CHEBI ID	51913
SCHEMBL ID	2175239
MeSH ID	M0216248

Synonym
CBIOL_001871
bdbm3033
3-{23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4(9),5,7,11(15),17,19,21-nonaen-3-yl}propanenitrile
chembl302449 ,
BRD-K59304176-001-02-5
BRD-K59304176-001-03-3
BSPBIO_001101
BIO2_000381
BIO1_000646
BIO2_000861
BIO1_000157
BIO1_001135
BCBCMAP01_000156
go6976
go 6976 ,
12h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-
3-[methyl(oxo)[?]yl]propanenitrile
goe 6976
136194-77-9
IDI1_002136
NCGC00163451-01
go-6976
13-methyl-5-oxo-5,6,7,13-tetrahydro-12h-indolo(2,3-a)pyrrolo(3,4-c)carbazole-12-propanenitrile
12h-indolo(2,3-a)pyrrolo(3,4-c)carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-
KBIO3_000822
KBIO2_000441
KBIOGR_000441
KBIO3_000821
KBIOSS_000441
KBIO2_005577
KBIO2_003009
NCGC00163451-02
3-(13-methyl-5-oxo-6,7-dihydro-5h-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12(13h)-yl)propanenitrile
3-(13-methyl-5-oxo-5,6,7,13-tetrahydro-12h-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)propanenitrile
CHEBI:51913 ,
12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5h-indolo[2,3-a]pyrolo[3,4-c]carbazole
g? 6976
HMS1990G03
HMS1362G03
HMS3229E13
EC-000.2399
HMS1792G03
KINOME_3630
3-(9-methyl-1-oxo-2,3-dihydro-1h-indolo[2,3-a]pyrrolo[3,4-c]carbazol-8(9h)-yl)propanenitrile
b9iqo7jz16 ,
unii-b9iqo7jz16
12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole
NCGC00163451-03
5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile
goe-6976
S7119
gouml 6976
3-{23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4,6,8,11(15),17,19,21-nonaen-3-yl}propanenitrile
gtpl5973
CCG-206755
EI-269
VWVYILCFSYNJHF-UHFFFAOYSA-N ,
c24h18n4o
SCHEMBL2175239
HB0302
AKOS024457007
HMS3403G03
FT-0697606
DTXSID70159731
g?? 6976, >=98% (hplc), powder
J-006821
NCGC00163451-04
BCP06797
go 6976 - cas 136194-77-9
Q27077832
3-(13-methyl-5-oxo-5,6,7,13-tetrahydro-12h-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)propionitrile
AS-16804
3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile
CS-0002498
HY-10183
AT23580
3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10.0^{4,9.0^{11,15.0^{17,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile
g ouml 6976
A924795
BG168444

Excerpt	Reference	Relevance
"To investigate the effect of GÖ6976 on the proliferation of chronic myeloid leukemia cells and its toxic effect on normal cells and mice, so as to provide experimental basis for the effectiveness and safety of its clinical application."	( [Effect of GÖ6976 on Proliferation of Chronic Myeloid Leukemia Cells and Its Toxicity on Normal Cells and Mice]. Cao, ZR; Chen, XP; Feng, M; Hu, J; Li, Y, 2020)	0.56
" Long-term application of 10 mg/kg and below concentrations of GÖ6976 shows no obvious toxic effect on BALB/c mice."	( [Effect of GÖ6976 on Proliferation of Chronic Myeloid Leukemia Cells and Its Toxicity on Normal Cells and Mice]. Cao, ZR; Chen, XP; Feng, M; Hu, J; Li, Y, 2020)	0.56

Excerpt	Reference	Relevance
" Vascular NO bioavailability as assessed with ESR spectroscopy using iron-thiocarbamate as a trap for NO was significantly reduced in tolerant vessels."	( Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Duncker, L; Förstermann, U; Hartmann, M; Hink, U; Li, H; Matheis, E; Meinertz, T; Mollnau, H; Münzel, T; Oelze, M; Skatchkov, M; Warnholtz, A, 2000)	0.31
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."	( Highly predictive and interpretable models for PAMPA permeability. Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017)	0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" The dose-response curve was bell shaped, with the maximal activation at 10(-9) M in 15 min."	( Rapid activation of ERK1/2 mitogen-activated protein kinase by corticosterone in PC12 cells. Chen, Y; Jing, Q; Li, X; Pei, G; Qiu, J; Sun, G; Wang, P; Zhang, W; Zhong, Y, 2001)	0.31
" The level of protein decreased around 50% after treatment for 3-5 days using the dosage of PMA effective against the mRNA expression."	( Protein kinase Cbeta isoform down-regulates the expression of MDR3 P-glycoprotein in human Chang liver cells. Hayashi, H; Kondo, T; Suzuki, S; Takagi, K; Ueyama, J; Wakusawa, S, 2006)	0.33
" In dose-response studies using IRHC, E(2)17G (3."	( Ca(2+)-dependent protein kinase C isoforms are critical to estradiol 17beta-D-glucuronide-induced cholestasis in the rat. Crocenzi, FA; Mottino, AD; Roma, MG; Ruiz, ML; Sánchez Pozzi, EJ; Vore, M; Zucchetti, AE, 2008)	0.35
" However, these inhibitors have yet to prove clinically efficacious, and their toxicity in skin, reflecting activity against wild-type EGFR, may limit dosing required to effectively suppress EGFR T790M in vivo."	( Noncovalent wild-type-sparing inhibitors of EGFR T790M. Chan, E; Heffron, TP; La, H; Lee, HJ; Malek, S; Merchant, M; Pirazzoli, V; Politi, K; Schaefer, G; Settleman, J; Shao, L; Sideris, S; Ubhayakar, S; Yauch, RL; Ye, X, 2013)	0.39
" Dexmedetomidine dose-response curves were generated in the presence or absence of the following inhibitors: the pan-PKC inhibitor, chelerythrine; the PKC-α and -β inhibitor, Go6976; the PKC-α inhibitor, safingol; the PKC-β inhibitor, ruboxistaurin; the PKC-δ inhibitor, rottlerin; the c-Jun NH2-terminal kinase (JNK) inhibitor, SP600125; and the myosin light chain kinase inhibitor, ML-7 hydrochloride."	( Dexmedetomidine-Induced Contraction in the Isolated Endothelium-Denuded Rat Aorta Involves PKC-δ-mediated JNK Phosphorylation. Cho, H; Choi, MJ; Chung, YK; Kim, WH; Kwon, SC; Lee, HK; Ok, SH; Park, J; Shin, IW; Sohn, JT; Yu, J, 2015)	0.42

Role	Description
EC 2.7.11.13 (protein kinase C) inhibitor	An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
organic heterohexacyclic compound
indolocarbazole	Compounds based upon an indolo[2,3-a]carbazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	11.2202	5.6234	17.2929	31.6228	AID485281
Fumarate hydratase	Homo sapiens (human)	Potency	1.1770	0.0030	8.7949	48.0869	AID1347053
PPM1D protein	Homo sapiens (human)	Potency	20.8212	0.0052	9.4661	32.9993	AID1347411
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	0.7519	0.5318	15.4358	37.6858	AID504845
EWS/FLI fusion protein	Homo sapiens (human)	Potency	3.7827	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
polyprotein	Zika virus	Potency	1.1770	0.0030	8.7949	48.0869	AID1347053
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	5.0119	0.1259	12.2344	35.4813	AID1458
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	31.6228	0.2512	15.8432	39.8107	AID504327
Interferon beta	Homo sapiens (human)	Potency	20.8212	0.0033	9.1582	39.8107	AID1347411
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	3.5481	1.0000	10.4756	28.1838	AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Serine/threonine-protein kinase PLK4	Homo sapiens (human)	Ki	8.6014	0.0003	0.9559	9.3000	AID1798514; AID762206
Protein kinase C gamma type	Homo sapiens (human)	IC50 (µMol)	0.0020	0.0001	1.0354	10.0000	AID325570
Protein kinase C beta type	Homo sapiens (human)	IC50 (µMol)	0.0041	0.0001	0.5542	10.0000	AID325569; AID357128
Protein kinase C alpha type	Homo sapiens (human)	IC50 (µMol)	0.0027	0.0001	0.9720	10.0000	AID325568; AID357127; AID500086
Serine/threonine-protein kinase PLK1	Homo sapiens (human)	Ki	10.7509	0.0002	1.0608	9.3000	AID1798514
Protein kinase C delta type	Homo sapiens (human)	IC50 (µMol)	0.4460	0.0001	0.8448	10.0000	AID500085
Serine/threonine-protein kinase D1	Homo sapiens (human)	IC50 (µMol)	0.0445	0.0001	1.2319	10.0000	AID500088; AID500089
NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)	IC50 (µMol)	100.0000	0.5000	3.8481	10.0000	AID274367
Serine/threonine-protein kinase PLK3	Homo sapiens (human)	Ki	10.7509	0.0010	1.2726	9.3000	AID1798514
Serine/threonine-protein kinase PLK2	Homo sapiens (human)	Ki	10.7509	0.0010	1.2726	9.3000	AID1798514
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
positive regulation of centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cilium assembly	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
trophoblast giant cell differentiation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
de novo centriole assembly involved in multi-ciliated epithelial cell differentiation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
protein phosphorylation	Protein kinase C gamma type	Homo sapiens (human)
chemical synaptic transmission	Protein kinase C gamma type	Homo sapiens (human)
learning or memory	Protein kinase C gamma type	Homo sapiens (human)
chemosensory behavior	Protein kinase C gamma type	Homo sapiens (human)
response to toxic substance	Protein kinase C gamma type	Homo sapiens (human)
phosphorylation	Protein kinase C gamma type	Homo sapiens (human)
negative regulation of protein ubiquitination	Protein kinase C gamma type	Homo sapiens (human)
regulation of response to food	Protein kinase C gamma type	Homo sapiens (human)
positive regulation of mismatch repair	Protein kinase C gamma type	Homo sapiens (human)
negative regulation of protein catabolic process	Protein kinase C gamma type	Homo sapiens (human)
regulation of circadian rhythm	Protein kinase C gamma type	Homo sapiens (human)
response to morphine	Protein kinase C gamma type	Homo sapiens (human)
negative regulation of neuron apoptotic process	Protein kinase C gamma type	Homo sapiens (human)
response to pain	Protein kinase C gamma type	Homo sapiens (human)
rhythmic process	Protein kinase C gamma type	Homo sapiens (human)
regulation of phagocytosis	Protein kinase C gamma type	Homo sapiens (human)
long-term synaptic potentiation	Protein kinase C gamma type	Homo sapiens (human)
innervation	Protein kinase C gamma type	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Protein kinase C gamma type	Homo sapiens (human)
negative regulation of proteasomal protein catabolic process	Protein kinase C gamma type	Homo sapiens (human)
response to psychosocial stress	Protein kinase C gamma type	Homo sapiens (human)
regulation of synaptic vesicle exocytosis	Protein kinase C gamma type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C gamma type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C gamma type	Homo sapiens (human)
adaptive immune response	Protein kinase C beta type	Homo sapiens (human)
chromatin remodeling	Protein kinase C beta type	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Protein kinase C beta type	Homo sapiens (human)
protein phosphorylation	Protein kinase C beta type	Homo sapiens (human)
calcium ion transport	Protein kinase C beta type	Homo sapiens (human)
intracellular calcium ion homeostasis	Protein kinase C beta type	Homo sapiens (human)
apoptotic process	Protein kinase C beta type	Homo sapiens (human)
mitotic nuclear membrane disassembly	Protein kinase C beta type	Homo sapiens (human)
signal transduction	Protein kinase C beta type	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Protein kinase C beta type	Homo sapiens (human)
response to xenobiotic stimulus	Protein kinase C beta type	Homo sapiens (human)
response to glucose	Protein kinase C beta type	Homo sapiens (human)
regulation of glucose transmembrane transport	Protein kinase C beta type	Homo sapiens (human)
negative regulation of glucose transmembrane transport	Protein kinase C beta type	Homo sapiens (human)
regulation of dopamine secretion	Protein kinase C beta type	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Protein kinase C beta type	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Protein kinase C beta type	Homo sapiens (human)
positive regulation of insulin secretion	Protein kinase C beta type	Homo sapiens (human)
response to vitamin D	Protein kinase C beta type	Homo sapiens (human)
regulation of growth	Protein kinase C beta type	Homo sapiens (human)
B cell activation	Protein kinase C beta type	Homo sapiens (human)
positive regulation of odontogenesis of dentin-containing tooth	Protein kinase C beta type	Homo sapiens (human)
lipoprotein transport	Protein kinase C beta type	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Protein kinase C beta type	Homo sapiens (human)
post-translational protein modification	Protein kinase C beta type	Homo sapiens (human)
response to ethanol	Protein kinase C beta type	Homo sapiens (human)
positive regulation of angiogenesis	Protein kinase C beta type	Homo sapiens (human)
positive regulation of DNA-templated transcription	Protein kinase C beta type	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Protein kinase C beta type	Homo sapiens (human)
B cell receptor signaling pathway	Protein kinase C beta type	Homo sapiens (human)
positive regulation of B cell receptor signaling pathway	Protein kinase C beta type	Homo sapiens (human)
cellular response to carbohydrate stimulus	Protein kinase C beta type	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Protein kinase C beta type	Homo sapiens (human)
regulation of synaptic vesicle exocytosis	Protein kinase C beta type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C beta type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C beta type	Homo sapiens (human)
angiogenesis	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Protein kinase C alpha type	Homo sapiens (human)
desmosome assembly	Protein kinase C alpha type	Homo sapiens (human)
chromatin remodeling	Protein kinase C alpha type	Homo sapiens (human)
protein phosphorylation	Protein kinase C alpha type	Homo sapiens (human)
mitotic nuclear membrane disassembly	Protein kinase C alpha type	Homo sapiens (human)
cell adhesion	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of endothelial cell migration	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Protein kinase C alpha type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C alpha type	Homo sapiens (human)
peptidyl-threonine phosphorylation	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of cell migration	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
negative regulation of glial cell apoptotic process	Protein kinase C alpha type	Homo sapiens (human)
regulation of mRNA stability	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Protein kinase C alpha type	Homo sapiens (human)
post-translational protein modification	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of macrophage differentiation	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of angiogenesis	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of bone resorption	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of cell adhesion	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of mitotic cell cycle	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Protein kinase C alpha type	Homo sapiens (human)
response to interleukin-1	Protein kinase C alpha type	Homo sapiens (human)
regulation of platelet aggregation	Protein kinase C alpha type	Homo sapiens (human)
apoptotic signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of angiotensin-activated signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of dense core granule biogenesis	Protein kinase C alpha type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of insulin secretion	Protein kinase C alpha type	Homo sapiens (human)
establishment of protein localization	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic sister chromatid segregation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
establishment of mitotic spindle orientation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic cytokinesis	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
microtubule bundle formation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
double-strand break repair	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic spindle organization	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
sister chromatid cohesion	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic chromosome condensation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic nuclear membrane disassembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
metaphase/anaphase transition of mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic spindle assembly checkpoint signaling	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centrosome cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
female meiosis chromosome segregation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein ubiquitination	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic metaphase/anaphase transition	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein destabilization	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of cytokinesis	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of protein binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
homologous chromosome segregation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of proteolysis	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
Golgi inheritance	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nuclear membrane disassembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of ubiquitin-protein transferase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
synaptonemal complex disassembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein localization to chromatin	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein localization to nuclear envelope	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
double-strand break repair via alternative nonhomologous end joining	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of protein localization to nucleus	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic spindle assembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of ubiquitin protein ligase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of protein localization to cell cortex	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic process	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein phosphorylation	Protein kinase C delta type	Homo sapiens (human)
apoptotic process	Protein kinase C delta type	Homo sapiens (human)
DNA damage response	Protein kinase C delta type	Homo sapiens (human)
signal transduction	Protein kinase C delta type	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	Protein kinase C delta type	Homo sapiens (human)
regulation of signaling receptor activity	Protein kinase C delta type	Homo sapiens (human)
immunoglobulin mediated immune response	Protein kinase C delta type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C delta type	Homo sapiens (human)
peptidyl-threonine phosphorylation	Protein kinase C delta type	Homo sapiens (human)
termination of signal transduction	Protein kinase C delta type	Homo sapiens (human)
negative regulation of actin filament polymerization	Protein kinase C delta type	Homo sapiens (human)
positive regulation of endodeoxyribonuclease activity	Protein kinase C delta type	Homo sapiens (human)
negative regulation of protein binding	Protein kinase C delta type	Homo sapiens (human)
activation of protein kinase activity	Protein kinase C delta type	Homo sapiens (human)
positive regulation of superoxide anion generation	Protein kinase C delta type	Homo sapiens (human)
regulation of actin cytoskeleton organization	Protein kinase C delta type	Homo sapiens (human)
negative regulation of glial cell apoptotic process	Protein kinase C delta type	Homo sapiens (human)
cellular response to UV	Protein kinase C delta type	Homo sapiens (human)
positive regulation of protein dephosphorylation	Protein kinase C delta type	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Protein kinase C delta type	Homo sapiens (human)
B cell proliferation	Protein kinase C delta type	Homo sapiens (human)
neutrophil activation	Protein kinase C delta type	Homo sapiens (human)
positive regulation of protein import into nucleus	Protein kinase C delta type	Homo sapiens (human)
defense response to bacterium	Protein kinase C delta type	Homo sapiens (human)
negative regulation of MAP kinase activity	Protein kinase C delta type	Homo sapiens (human)
regulation of mRNA stability	Protein kinase C delta type	Homo sapiens (human)
post-translational protein modification	Protein kinase C delta type	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Protein kinase C delta type	Homo sapiens (human)
negative regulation of inflammatory response	Protein kinase C delta type	Homo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylation	Protein kinase C delta type	Homo sapiens (human)
protein stabilization	Protein kinase C delta type	Homo sapiens (human)
negative regulation of filopodium assembly	Protein kinase C delta type	Homo sapiens (human)
cell chemotaxis	Protein kinase C delta type	Homo sapiens (human)
cellular response to hydrogen peroxide	Protein kinase C delta type	Homo sapiens (human)
cellular response to hydroperoxide	Protein kinase C delta type	Homo sapiens (human)
negative regulation of platelet aggregation	Protein kinase C delta type	Homo sapiens (human)
cellular senescence	Protein kinase C delta type	Homo sapiens (human)
positive regulation of phospholipid scramblase activity	Protein kinase C delta type	Homo sapiens (human)
cellular response to angiotensin	Protein kinase C delta type	Homo sapiens (human)
regulation of ceramide biosynthetic process	Protein kinase C delta type	Homo sapiens (human)
positive regulation of ceramide biosynthetic process	Protein kinase C delta type	Homo sapiens (human)
positive regulation of glucosylceramide catabolic process	Protein kinase C delta type	Homo sapiens (human)
positive regulation of sphingomyelin catabolic process	Protein kinase C delta type	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Protein kinase C delta type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C delta type	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase D1	Homo sapiens (human)
angiogenesis	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Serine/threonine-protein kinase D1	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase D1	Homo sapiens (human)
inflammatory response	Serine/threonine-protein kinase D1	Homo sapiens (human)
Golgi organization	Serine/threonine-protein kinase D1	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase D1	Homo sapiens (human)
integrin-mediated signaling pathway	Serine/threonine-protein kinase D1	Homo sapiens (human)
nervous system development	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of autophagy	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of endothelial cell migration	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of gene expression	Serine/threonine-protein kinase D1	Homo sapiens (human)
regulation of keratinocyte proliferation	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of neuron projection development	Serine/threonine-protein kinase D1	Homo sapiens (human)
regulation of skeletal muscle contraction by modulation of calcium ion sensitivity of myofibril	Serine/threonine-protein kinase D1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase D1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase D1	Homo sapiens (human)
sphingolipid biosynthetic process	Serine/threonine-protein kinase D1	Homo sapiens (human)
cell differentiation	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Serine/threonine-protein kinase D1	Homo sapiens (human)
cellular response to amino acid starvation	Serine/threonine-protein kinase D1	Homo sapiens (human)
cellular response to oxidative stress	Serine/threonine-protein kinase D1	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase D1	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of protein import into nucleus	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Serine/threonine-protein kinase D1	Homo sapiens (human)
innate immune response	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of osteoblast differentiation	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of angiogenesis	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of cell size	Serine/threonine-protein kinase D1	Homo sapiens (human)
negative regulation of endocytosis	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase D1	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of protein export from nucleus	Serine/threonine-protein kinase D1	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Serine/threonine-protein kinase D1	Homo sapiens (human)
Golgi vesicle transport	Serine/threonine-protein kinase D1	Homo sapiens (human)
defense response to Gram-negative bacterium	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Serine/threonine-protein kinase D1	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of sarcomere organization	Serine/threonine-protein kinase D1	Homo sapiens (human)
cellular response to hydroperoxide	Serine/threonine-protein kinase D1	Homo sapiens (human)
cellular response to norepinephrine stimulus	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of peptide hormone secretion	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assembly	Serine/threonine-protein kinase D1	Homo sapiens (human)
cellular response to angiotensin	Serine/threonine-protein kinase D1	Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristate	Serine/threonine-protein kinase D1	Homo sapiens (human)
cellular response to endothelin	Serine/threonine-protein kinase D1	Homo sapiens (human)
positive regulation of endothelial cell chemotaxis	Serine/threonine-protein kinase D1	Homo sapiens (human)
regulation of integrin-mediated signaling pathway	Serine/threonine-protein kinase D1	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Serine/threonine-protein kinase D1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
rDNA heterochromatin formation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
protein deacetylation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
autophagy	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
mitotic nuclear membrane reassembly	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
regulation of exit from mitosis	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of autophagy	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
substantia nigra development	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
myelination in peripheral nervous system	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
heterochromatin formation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
subtelomeric heterochromatin formation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
regulation of myelination	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cellular response to oxidative stress	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
peptidyl-lysine deacetylation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
epigenetic regulation of gene expression	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of protein catabolic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
regulation of phosphorylation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of DNA binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
post-translational protein modification	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cellular lipid catabolic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NLRP3 inflammasome complex assembly	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
innate immune response	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of fat cell differentiation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of fatty acid biosynthetic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of meiotic nuclear division	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of striated muscle tissue development	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of DNA-templated transcription	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cell division	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
meiotic cell cycle	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
regulation of cell cycle	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
response to redox state	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of cell division	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochore	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cellular response to caloric restriction	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of oligodendrocyte progenitor proliferation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cellular response to hypoxia	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cellular response to epinephrine stimulus	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
tubulin deacetylation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of execution phase of apoptosis	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of oocyte maturation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assembly	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of satellite cell differentiation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
response to reactive oxygen species	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
response to osmotic stress	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
endomitotic cell cycle	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
response to radiation	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
cytoplasmic microtubule organization	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
regulation of cytokinesis	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
mitotic G1/S transition checkpoint signaling	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
regulation of cell division	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
Golgi disassembly	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
positive regulation of intracellular protein transport	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
positive regulation of chaperone-mediated autophagy	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxia	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
mitotic spindle organization	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
mitotic spindle organization	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
Ras protein signal transduction	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
memory	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
positive regulation of autophagy	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
negative regulation of angiogenesis	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
Rap protein signal transduction	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
positive regulation of protein catabolic process	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
regulation of centriole replication	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
regulation of synaptic plasticity	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
long-term synaptic potentiation	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
long-term synaptic depression	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
negative regulation of apoptotic process in bone marrow cell	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
negative regulation of cellular senescence	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
protein kinase activity	Protein kinase C gamma type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C gamma type	Homo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C gamma type	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Protein kinase C gamma type	Homo sapiens (human)
protein binding	Protein kinase C gamma type	Homo sapiens (human)
ATP binding	Protein kinase C gamma type	Homo sapiens (human)
zinc ion binding	Protein kinase C gamma type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C gamma type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C gamma type	Homo sapiens (human)
chromatin binding	Protein kinase C beta type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C beta type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C beta type	Homo sapiens (human)
protein kinase C binding	Protein kinase C beta type	Homo sapiens (human)
calcium channel regulator activity	Protein kinase C beta type	Homo sapiens (human)
protein binding	Protein kinase C beta type	Homo sapiens (human)
ATP binding	Protein kinase C beta type	Homo sapiens (human)
zinc ion binding	Protein kinase C beta type	Homo sapiens (human)
nuclear receptor coactivator activity	Protein kinase C beta type	Homo sapiens (human)
histone H3T6 kinase activity	Protein kinase C beta type	Homo sapiens (human)
histone binding	Protein kinase C beta type	Homo sapiens (human)
nuclear androgen receptor binding	Protein kinase C beta type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C beta type	Homo sapiens (human)
protein kinase activity	Protein kinase C alpha type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
integrin binding	Protein kinase C alpha type	Homo sapiens (human)
protein binding	Protein kinase C alpha type	Homo sapiens (human)
ATP binding	Protein kinase C alpha type	Homo sapiens (human)
zinc ion binding	Protein kinase C alpha type	Homo sapiens (human)
enzyme binding	Protein kinase C alpha type	Homo sapiens (human)
histone H3T6 kinase activity	Protein kinase C alpha type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
diacylglycerol binding	Protein kinase C alpha type	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
microtubule binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
anaphase-promoting complex binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein kinase binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein kinase activity	Protein kinase C delta type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C delta type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C delta type	Homo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activity	Protein kinase C delta type	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Protein kinase C delta type	Homo sapiens (human)
protein binding	Protein kinase C delta type	Homo sapiens (human)
ATP binding	Protein kinase C delta type	Homo sapiens (human)
enzyme activator activity	Protein kinase C delta type	Homo sapiens (human)
enzyme binding	Protein kinase C delta type	Homo sapiens (human)
protein kinase binding	Protein kinase C delta type	Homo sapiens (human)
insulin receptor substrate binding	Protein kinase C delta type	Homo sapiens (human)
metal ion binding	Protein kinase C delta type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C delta type	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase D1	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Serine/threonine-protein kinase D1	Homo sapiens (human)
protein kinase C binding	Serine/threonine-protein kinase D1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase D1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase D1	Homo sapiens (human)
kinase activity	Serine/threonine-protein kinase D1	Homo sapiens (human)
heat shock protein binding	Serine/threonine-protein kinase D1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase D1	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase D1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase D1	Homo sapiens (human)
phosphatidylinositol 3-kinase activator activity	Serine/threonine-protein kinase D1	Homo sapiens (human)
NAD+ ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
chromatin binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD+ ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
histone deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
protein binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
zinc ion binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD-dependent histone deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
protein lysine deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD-dependent protein lysine deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
histone acetyltransferase binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
histone deacetylase binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
tubulin deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
ubiquitin binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD+ binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
DNA-binding transcription factor binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD-dependent protein demyristoylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD-dependent protein depalmitoylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
transcription factor binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
p53 binding	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
ATP-dependent protein binding	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
XY body	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cleavage furrow	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
deuterosome	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
procentriole	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
procentriole replication complex	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
nucleus	Protein kinase C gamma type	Homo sapiens (human)
cytosol	Protein kinase C gamma type	Homo sapiens (human)
plasma membrane	Protein kinase C gamma type	Homo sapiens (human)
cell-cell junction	Protein kinase C gamma type	Homo sapiens (human)
postsynaptic density	Protein kinase C gamma type	Homo sapiens (human)
dendrite	Protein kinase C gamma type	Homo sapiens (human)
calyx of Held	Protein kinase C gamma type	Homo sapiens (human)
perinuclear region of cytoplasm	Protein kinase C gamma type	Homo sapiens (human)
synaptic membrane	Protein kinase C gamma type	Homo sapiens (human)
presynaptic cytosol	Protein kinase C gamma type	Homo sapiens (human)
postsynaptic cytosol	Protein kinase C gamma type	Homo sapiens (human)
nucleus	Protein kinase C beta type	Homo sapiens (human)
nucleoplasm	Protein kinase C beta type	Homo sapiens (human)
cytoplasm	Protein kinase C beta type	Homo sapiens (human)
centrosome	Protein kinase C beta type	Homo sapiens (human)
cytosol	Protein kinase C beta type	Homo sapiens (human)
plasma membrane	Protein kinase C beta type	Homo sapiens (human)
brush border membrane	Protein kinase C beta type	Homo sapiens (human)
calyx of Held	Protein kinase C beta type	Homo sapiens (human)
extracellular exosome	Protein kinase C beta type	Homo sapiens (human)
presynaptic cytosol	Protein kinase C beta type	Homo sapiens (human)
spectrin	Protein kinase C beta type	Homo sapiens (human)
ciliary basal body	Protein kinase C alpha type	Homo sapiens (human)
nucleoplasm	Protein kinase C alpha type	Homo sapiens (human)
cytoplasm	Protein kinase C alpha type	Homo sapiens (human)
mitochondrion	Protein kinase C alpha type	Homo sapiens (human)
endoplasmic reticulum	Protein kinase C alpha type	Homo sapiens (human)
cytosol	Protein kinase C alpha type	Homo sapiens (human)
plasma membrane	Protein kinase C alpha type	Homo sapiens (human)
mitochondrial membrane	Protein kinase C alpha type	Homo sapiens (human)
perinuclear region of cytoplasm	Protein kinase C alpha type	Homo sapiens (human)
extracellular exosome	Protein kinase C alpha type	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Protein kinase C alpha type	Homo sapiens (human)
spindle microtubule	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
synaptonemal complex	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
microtubule cytoskeleton	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
midbody	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centriolar satellite	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle midzone	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic spindle pole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
chromatin	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
outer kinetochore	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
extracellular region	Protein kinase C delta type	Homo sapiens (human)
nucleus	Protein kinase C delta type	Homo sapiens (human)
nucleoplasm	Protein kinase C delta type	Homo sapiens (human)
cytoplasm	Protein kinase C delta type	Homo sapiens (human)
mitochondrion	Protein kinase C delta type	Homo sapiens (human)
endoplasmic reticulum	Protein kinase C delta type	Homo sapiens (human)
cytosol	Protein kinase C delta type	Homo sapiens (human)
plasma membrane	Protein kinase C delta type	Homo sapiens (human)
cell-cell junction	Protein kinase C delta type	Homo sapiens (human)
nuclear matrix	Protein kinase C delta type	Homo sapiens (human)
azurophil granule lumen	Protein kinase C delta type	Homo sapiens (human)
endolysosome	Protein kinase C delta type	Homo sapiens (human)
perinuclear region of cytoplasm	Protein kinase C delta type	Homo sapiens (human)
extracellular exosome	Protein kinase C delta type	Homo sapiens (human)
autophagosome membrane	Serine/threonine-protein kinase D1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase D1	Homo sapiens (human)
trans-Golgi network	Serine/threonine-protein kinase D1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase D1	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase D1	Homo sapiens (human)
cell-cell junction	Serine/threonine-protein kinase D1	Homo sapiens (human)
cell cortex	Serine/threonine-protein kinase D1	Homo sapiens (human)
Z disc	Serine/threonine-protein kinase D1	Homo sapiens (human)
perinuclear region of cytoplasm	Serine/threonine-protein kinase D1	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase D1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase D1	Homo sapiens (human)
chromosome, telomeric region	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
nucleus	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
chromosome	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
nucleolus	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cytoplasm	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
mitochondrion	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
centrosome	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
centriole	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
spindle	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cytosol	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
microtubule	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
plasma membrane	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
growth cone	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
midbody	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
paranodal junction	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
paranode region of axon	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
perikaryon	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
myelin sheath	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
lateral loop	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
Schmidt-Lanterman incisure	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
juxtaparanode region of axon	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
perinuclear region of cytoplasm	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
mitotic spindle	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
meiotic spindle	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
glial cell projection	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
heterochromatin	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
chromatin silencing complex	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
nucleus	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
Golgi stack	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
dendrite	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
neuronal cell body	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
dendrite	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
chromatin	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (644)

Assay ID	Title	Year	Journal	Article
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591	NCATS Rat Liver Microsome Stability Profiling	2020	Scientific reports, 11-26, Volume: 10, Issue:1	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1508612	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Highly predictive and interpretable models for PAMPA permeability.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID720277	Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720403	Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720178	Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720443	Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720432	Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720232	Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720320	Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720434	Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720245	Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720152	Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435237	Percentage JNK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720234	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435739	Percentage p38-gamma activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720033	Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720055	Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720045	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720084	Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720068	Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720361	Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720368	Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720356	Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720103	Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720436	Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720162	Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720164	Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720089	Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720129	Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720422	Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720248	Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID274366	Inhibition of human SIRT1	2006	Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25	Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
AID435882	Percentage RSK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720168	Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720267	Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720305	Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435875	Percentage PRAK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID512327	Inhibition of His-tagged human SAPK2b/p38b2 expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720136	Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435229	Percentage ERK8 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720307	Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720186	Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720457	Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720195	Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720313	Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720082	Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID357127	Inhibition of PKCalpha	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID500085	Inhibition of PKCdelta by TR-FRET assay	2010	Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15	Identification of orally available naphthyridine protein kinase D inhibitors.
AID720450	Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512337	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720437	Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720347	Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720254	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720075	Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720035	Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720350	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720185	Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720077	Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720352	Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720395	Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720328	Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325568	Inhibition of PKCalpha	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720175	Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720223	Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720154	Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720314	Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720374	Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720315	Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720094	Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720462	Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435112	Percentage MAPKAPK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720464	Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID500089	Inhibition of PKD1 assessed as HDAC5 neuclear export	2010	Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15	Identification of orally available naphthyridine protein kinase D inhibitors.
AID720409	Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720257	Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435437	Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720342	Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720441	Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720396	Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512339	Inhibition of His-tagged human S6K1 expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720134	Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720286	Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720029	Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720297	Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720188	Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720306	Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720435	Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID500087	Inhibition of PKD by TR-FRET assay	2010	Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15	Identification of orally available naphthyridine protein kinase D inhibitors.
AID720026	Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720206	Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720275	Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720169	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720220	Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720156	Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720404	Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720316	Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720080	Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435712	Percentage CHK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720417	Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720032	Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720355	Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720189	Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720105	Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512329	Inhibition of His-tagged human SAPK4/p38delta expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720289	Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720241	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512343	Inhibition of His-tagged human CK2 expressed in Sf9 cells at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720226	Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720285	Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435610	Percentage MAPKAPK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720410	Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720059	Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720427	Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720041	Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720360	Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720346	Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720027	Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720096	Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720128	Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720065	Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720092	Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720288	Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720130	Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435303	Percentage PHK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720472	Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID357130	Inhibition of IFN-gamma-induced IFN-gamma regulatory factor levels in Sprague-Dawley rat primary microglial cells by Western blotting	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID720078	Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720191	Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720031	Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720449	Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720478	Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720203	Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720063	Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435917	Percentage PAK6 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720256	Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720303	Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720030	Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720408	Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435222	Percentage CK1delta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720097	Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720155	Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720228	Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435825	Percentage PKCalpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720270	Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720416	Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720062	Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720278	Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720070	Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720201	Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435466	Percentage ERK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID512344	Inhibition of PHK from rabbit skeletal muscle at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720107	Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435715	Percentage DYRK1A activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720273	Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720287	Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720304	Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720238	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID357134	Inhibition of MHC2 expression in Sprague-Dawley rat peritoneal macrophages at 1.3 uM after 24 hrs by immunostaining	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID435740	Percentage PKCzeta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720151	Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720018	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720430	Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512324	Inhibition of His-tagged human MAPK2/ERK2 expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720463	Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512342	Inhibition of rat liver AMPK at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720406	Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512345	Inhibition of His-tagged human LCK expressed in Sf9 cells at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720110	Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720279	Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720034	Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720170	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720370	Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435299	Percentage PAK5 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435187	Percentage CDK2-cyclinA activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID325569	Inhibition of PKCbeta	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435467	Percentage ERK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720161	Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720391	Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720224	Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720101	Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720259	Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720108	Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID357132	Suppression of IFN-gamma-induced IFN-gamma regulatory factor 1 nuclear translocation in Sprague-Dawley rat primary microglial cells at 1.3 uM by Western blotting	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID720369	Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720414	Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720381	Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720397	Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720362	Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720135	Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720327	Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720214	Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720483	Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720137	Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720364	Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720204	Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720318	Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720124	Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720300	Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720253	Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720343	Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720358	Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435371	Percentage p38delta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720142	Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720271	Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720040	Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720239	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435755	Percentage SmMLCK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1364976	Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect measured on day 5 post infection by MTS/PMS based microscopic analysis	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	The medicinal chemistry of Chikungunya virus.
AID720149	Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720274	Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720292	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720376	Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720400	Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435976	Percentage MNK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720295	Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435477	Percentage MNK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720419	Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720385	Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435981	Percentage p38alpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720420	Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720182	Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720284	Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720474	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID357128	Inhibition of PKCbeta1	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID512336	Inhibition of His-tagged human PDK1 expressed in Sf21 cells at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720482	Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720174	Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720044	Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720088	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720177	Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720418	Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720122	Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720095	Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720477	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720480	Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720066	Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720202	Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720461	Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720415	Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720475	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435108	Percentage IKK-beta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720261	Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720072	Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID500088	Inhibition of PKD1 by TR-FRET assay	2010	Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15	Identification of orally available naphthyridine protein kinase D inhibitors.
AID720329	Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720266	Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720308	Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720394	Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720211	Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720023	Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720181	Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720367	Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720388	Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720383	Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720200	Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720090	Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720091	Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720021	Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720093	Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720047	Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720102	Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID274367	Inhibition of human recombinant SIRT2	2006	Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25	Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
AID720244	Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435538	Percentage PDK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720125	Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512334	Inhibition of bovine heart PKA at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720298	Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720126	Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720440	Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720058	Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435811	Percentage PIM1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436065	Percentage BRSK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720321	Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435732	Percentage MSK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID512338	Inhibition of His-tagged human SGK expressed in Sf9 cells at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720349	Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720143	Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720233	Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720423	Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435230	Percentage GSK3-beta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435127	Percentage PAK4 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720448	Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720468	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720036	Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720099	Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720163	Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720073	Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720351	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720425	Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720345	Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720372	Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720272	Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435470	Percentage HIPK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720302	Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720192	Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720117	Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720433	Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720348	Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720138	Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435839	Percentage AMPK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720074	Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720109	Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720460	Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512341	Inhibition of rat ROCK2 expressed in Sf9 cells at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720146	Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720198	Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435109	Percentage JNK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720290	Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435224	Percentage DYRK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720133	Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512326	Inhibition of His-tagged human SAPK2a/p38 expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720218	Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720421	Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720153	Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720222	Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720467	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720098	Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720067	Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720118	Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720252	Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720046	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720276	Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435132	Percentage Src activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720158	Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720337	Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720242	Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435498	Percentage RSK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435377	Percentage S6K1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720221	Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435111	Percentage Lck activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720451	Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720249	Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720017	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512335	Inhibition of His-tagged human PKCalpha expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720111	Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720100	Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435927	Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720390	Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435596	Percentage CSK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720309	Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720444	Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720179	Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720121	Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720196	Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720393	Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435346	Percentage EF2K activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720061	Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720336	Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720235	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID500086	Inhibition of PKCalpha by TR-FRET assay	2010	Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15	Identification of orally available naphthyridine protein kinase D inhibitors.
AID720076	Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720172	Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720384	Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720230	Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720087	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720411	Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720331	Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435880	Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435359	Percentage JNK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720237	Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720171	Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435216	Percentage Aurora B activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720043	Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720115	Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720431	Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720022	Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720281	Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720317	Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720301	Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720293	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720052	Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720454	Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720208	Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720412	Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720470	Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720333	Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720205	Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720379	Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720466	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720160	Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720114	Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720049	Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436035	Percentage CaMKKbeta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720227	Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720056	Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720326	Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720183	Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720465	Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720180	Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720048	Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720484	Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720086	Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720025	Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720231	Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720028	Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720373	Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720123	Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720247	Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720445	Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720166	Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720197	Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720144	Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720176	Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720366	Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720476	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512325	Inhibition of His-tagged human JNK1a1/SAPK1c expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720399	Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720386	Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720323	Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720405	Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720452	Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720334	Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435735	Percentage NEK7 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720382	Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435362	Percentage MELK activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720363	Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720215	Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720081	Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720250	Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720294	Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720260	Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720190	Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720060	Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720471	Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720447	Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720357	Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435457	Percentage CHK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720312	Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720424	Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720120	Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720051	Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435128	Percentage PKD1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720407	Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID357115	Decrease in IFN-gamma-induced MHC2 expression in Sprague-Dawley rat primary microglial cells at 1.3 uM	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID720375	Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720481	Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720085	Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435251	Percentage MST2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720019	Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720141	Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720165	Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720053	Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720377	Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID357131	Suppression of IFN-gamma-induced PKCalpha/beta2 nuclear translocation in Sprague-Dawley rat primary microglial cells at 1.3 uM by Western blotting	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID720262	Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720038	Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720438	Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435921	Percentage PIM2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720132	Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720344	Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720291	Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435134	Percentage SRPK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720225	Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720365	Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720020	Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512340	Inhibition of His-tagged human GSK3b expressed in Sf21 cells at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720037	Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720039	Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720413	Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720069	Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720473	Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435617	Percentage NEK6 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720283	Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720193	Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720455	Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720338	Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720324	Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720330	Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720127	Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720207	Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720187	Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720145	Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720268	Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435633	Percentage SGK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435475	Percentage MKK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720401	Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720212	Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720339	Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720354	Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720184	Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720106	Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720217	Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720243	Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720446	Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID762206	Inhibition of human PLK4	2013	Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15	The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
AID720050	Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720246	Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435870	Percentage p38beta activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID512346	Inhibition of His-tagged human CHK1 expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720378	Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720148	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720459	Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512330	Inhibition of MAPKAPK1b from rabbit skeletal muscle at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID435435	Percentage CaMK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720353	Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720387	Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720213	Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720258	Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720139	Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720167	Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720453	Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720265	Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435611	Percentage MARK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720116	Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720071	Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID503314	Antiproliferative activity against human PC3 cells at 100 nM after 120 hrs by MTT assay relative to DMSO	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID720398	Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720251	Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720380	Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720389	Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720269	Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720402	Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720236	Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720054	Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720173	Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720428	Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435594	Percentage CK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720199	Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720322	Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435366	Percentage NEK2a activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720319	Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720296	Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720159	Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720325	Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID357379	Decrease in IFN-gamma-induced MHC2 protein levels in Sprague-Dawley rat primary microglial cells at 1.3 uM by Western blotting	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID720064	Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720083	Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435598	Percentage DYRK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720157	Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720299	Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720340	Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720229	Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720310	Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512328	Inhibition of His-tagged human SAPK3/p38gamma expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720140	Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720112	Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720282	Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435217	Percentage Aurora C activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720042	Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720113	Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720280	Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720359	Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720341	Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435922	Percentage PIM3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720469	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720024	Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1364977	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured on day 5 post dose by MTS/PMS based microscopic analysis	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	The medicinal chemistry of Chikungunya virus.
AID720263	Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720458	Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720147	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720311	Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435354	Percentage HIPK3 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720240	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512331	Inhibition of His-tagged human MAPKAPK2 expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720119	Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720104	Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512333	Inhibition of His-tagged human PRAK expressed in Sf9 cells at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID435305	Percentage PKA activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720219	Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720255	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435548	Percentage CaMKKalpha activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720426	Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720209	Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720332	Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720479	Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720150	Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325570	Inhibition of PKCgamma	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720079	Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720264	Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435873	Percentage PLK1 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID512332	Inhibition of His-tagged human MSK1 expressed in Sf9 cells at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720131	Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720210	Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720429	Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720439	Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720456	Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720216	Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512323	Inhibition of rabbit MKK1 expressed in Escherichia coli at 1 uM	2000	The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID720335	Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720442	Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720057	Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720194	Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720392	Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435878	Percentage PRK2 activity remaining in the presence of 0.1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID720371	Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848	NCATS Kinetic Aqueous Solubility Profiling	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID493040	Navigating the Kinome	2011	Nature chemical biology, Apr, Volume: 7, Issue:4	Navigating the kinome.
AID1798514	PLK Kinase Assay from Article 10.1021/bi7008745: \\Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.\\	2007	Biochemistry, Aug-21, Volume: 46, Issue:33	Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
AID1345407	Human protein kinase C alpha (Delta subfamily)	1993	The Journal of biological chemistry, May-05, Volume: 268, Issue:13	Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976.
AID1345351	Human protein kinase D1 (Protein kinase D (PKD) family)	1996	FEBS letters, Aug-26, Volume: 392, Issue:2	Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	57 (11.49)	18.2507
2000's	285 (57.46)	29.6817
2010's	140 (28.23)	24.3611
2020's	14 (2.82)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (0.20%)	5.53%
Reviews	2 (0.40%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	501 (99.40%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phosphoserine Phosphoserine: The phosphoric acid ester of serine.	3.12	5	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite
acetaldehyde Acetaldehyde: A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis.. acetaldehyde : The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.. aldehyde : A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.. acetyl group : A group, formally derived from acetic acid by dehydroxylation, which is fundamental to the biochemistry of all forms of life. When bound to coenzyme A, it is central to the metabolism of carbohydrates and fats.	2.02	1	aldehyde	carcinogenic agent; EC 3.5.1.4 (amidase) inhibitor; electron acceptor; Escherichia coli metabolite; human metabolite; mouse metabolite; mutagen; oxidising agent; Saccharomyces cerevisiae metabolite; teratogenic agent
1-butanol 1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1.. butan-1-ol : A primary alcohol that is butane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It it produced in small amounts in humans by the gut microbes.	2.42	2	alkyl alcohol; primary alcohol; short-chain primary fatty alcohol	human metabolite; mouse metabolite; protic solvent
formic acid formic acid: RN given refers to parent cpd. formic acid : The simplest carboxylic acid, containing a single carbon. Occurs naturally in various sources including the venom of bee and ant stings, and is a useful organic synthetic reagent. Principally used as a preservative and antibacterial agent in livestock feed. Induces severe metabolic acidosis and ocular injury in human subjects.	2.03	1	monocarboxylic acid	antibacterial agent; astringent; metabolite; protic solvent; solvent
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.73	3	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
gallic acid gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.	2.44	2	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite
glycine [no description available]	2.41	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	2.03	1	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
histamine [no description available]	3.27	6	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
melatonin [no description available]	2.15	1	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.03	1	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	2	1	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
spermine [no description available]	2.03	1	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
taurine [no description available]	2.04	1	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	2.17	1	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
isopentenyl pyrophosphate isopentenyl pyrophosphate: substrate for isopentenyl pyrophosphate isomerase; RN given refers to unlabeled cpd; a nonpeptide mycobacterial antigen that stimulates gamma delta T cells. isopentenyl diphosphate : A prenol phosphate comprising 3-methylbut-3-en-1-ol having an O-diphosphate substituent.	2.01	1	prenol phosphate	antigen; antioxidant; epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen
2-amino-5-phosphonovalerate 2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.	2	1	non-proteinogenic alpha-amino acid	NMDA receptor antagonist
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.	2.03	1	non-proteinogenic alpha-amino acid
4-iodo-2,5-dimethoxyphenylisopropylamine 4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist. 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.	2.06	1	amphetamines; dimethoxybenzene; organoiodine compound
b 844-39 [no description available]	2.15	1	diarylmethane
1,2-dioctanoylglycerol 1,2-dioctanoylglycerol: functions as bioregulator of protein kinase C in human platelets	2.72	3
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	2.89	3	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
edelfosine edelfosine: RN given refers to parent cpd. edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.. 1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.	2.43	2	glycerophosphocholine
pd 173074 [no description available]	2.03	1	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
2-aminoethoxydiphenyl borate 2-aminoethoxydiphenyl borate: is a novel membrane-penetrable modulator and transient receptor potential channel blocker; structure in first source; do not confuse with 2-APB cpd. 2-aminoethoxydiphenylborane : An organoboron compound that is diphenylborane in which the borane hydrogen is replaced by a 2-aminoethoxy group.	2.51	2	organoboron compound; primary amino compound	calcium channel blocker; IP3 receptor antagonist; potassium channel opener
4,5,6,7-tetrabromo-2-azabenzimidazole 4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor	2.03	1
jtv519 [no description available]	2.89	3
4-diphenylacetoxy-1,1-dimethylpiperidinium 4-diphenylacetoxy-1,1-dimethylpiperidinium: muscarinic receptor antagonist; RN given refers to parent cpd; do not confuse abbreviation 4-DAMP with a similar cpd which does not contain dimethyl groups. 4-DAMP(1+) : A quaternary ammonium salt obtained by formal methylation of the tertiary amino function of 4-diphenylacetoxy-N-methylpiperidine.	2.02	1	quaternary ammonium ion	cholinergic antagonist; muscarinic antagonist
5-(n,n-hexamethylene)amiloride 5-(N,N-hexamethylene)amiloride: inhibitor of Na+-H+ exchange; has anti-HIV-1 activity. 5-(N,N-hexamethylene)amiloride : A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring.	2.07	1	aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines	antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker
N-(2-aminoethyl)-5-chloro-1-naphthalenesulfonamide [no description available]	2.03	1	naphthalenes; sulfonic acid derivative
tyrphostin ag 1024 tyrphostin AG 1024: modulates radiosensitivity in human breast cancer cells; also an IGF1 receptor inhibitor	2.08	1	alkylbenzene
ag 1295 [no description available]	2.46	2	quinoxaline derivative	geroprotector
ag-1296 6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase	2.46	2	quinoxaline derivative
rtki cpd [no description available]	2.08	1	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector
tyrphostin a23 tyrphostin A23: inhibits EGF-stimulated thymidine incorporation as well as EGF-stimulated receptor autophosphorylation & tyrosine phosphorylation & cell proliferation; structure given in first source	2.42	2	catechols
tyrphostin a1 [no description available]	2.08	1	methoxybenzenes	geroprotector
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	2.03	1	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	2.89	3	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.03	1	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	2.05	1	N-acylglycine	Daphnia magna metabolite
dan 2163 [no description available]	2.89	3	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.89	3	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
acetovanillone apocynin : An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3.	2.07	1	acetophenones; aromatic ketone; methyl ketone	antirheumatic drug; EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug; plant metabolite
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.89	3	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
azelastine azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.	2.02	1	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
baclofen [no description available]	2.07	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
bay-k-8644 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.. Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644. methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6.	2.69	3	(trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	2.89	3	1-benzofurans; aromatic ketone	uricosuric drug
berberine [no description available]	3.59	2	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
2,5-di-tert-butylhydroquinone 2,5-di-tert-butylbenzene-1,4-diol : A member of the class of hydroquinones that is benzene-1,4-diol substituted by tert-butyl groups at position 2 and 5.	2	1	hydroquinones
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.03	1	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide [no description available]	2.06	1	hydroxycinnamic acid
bisindolylmaleimide i bisindolylmaleimide I: a bis(indolyl)maleimide	6.84	82
2-(1-(2-(1-methylpyrrolidino)ethyl)-1h-indol-3-yl)maleimide bisindolylmaleimide II: protein kinase C inhibitor; see also bisindolylmaleimide I	2.03	1
bisindolylmaleimide iii bisindolylmaleimide III: structure in first source	2	1	indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
bisindolylmaleimide iv [no description available]	2.95	4	indoles; maleimides
bisindolylmaleimide v bisindolylmaleimide V: used as a negative control compound for protein kinase C inhibition; structure in first source;	2.42	2	indoles
ro 31-7549 Ro 31-7549: structure	2.7	3
ro 31-8425 [no description available]	2	1
bohemine bohemine : Purine substituted on C-2, C-6 and N-9 with (3-hydroxypropyl)amino, benzylamino and isopropyl groups respectively; a synthetic, cell-permeable, cyclin-dependent kinase (CDK) inhibitor that is structurally similar to olomoucine and roscovitine.	2.46	2	purines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bufexamac Bufexamac: A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally.. bufexamac : A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties.	2.89	3	aromatic ether; hydroxamic acid	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cadralazine cadralazine: structure given in first source	2.89	3	organic molecular entity
caffeine [no description available]	3.12	5	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.42	2	aromatic ether; nitrile; polyether; tertiary amino compound
candesartan candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.	2.05	1	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carvedilol [no description available]	2.63	2	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
celecoxib [no description available]	2.03	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	2.63	2	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
cgp 37157 CGP 37157: benzothiazepine derivative of clonazepam; inhibits the in vitro activity of mitochondrial sodium-calcium exchange	2.02	1	benzothiazepine
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	4.28	18	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
chlorcyclizine chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness	2.89	3	diarylmethane
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	3.25	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
ci 994 tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.	2.89	3	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	2.03	1	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
ciprofibrate [no description available]	2.03	1	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
clenbuterol Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.. clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.03	1	amino alcohol; dichlorobenzene; ethanolamines; primary arylamine; secondary amino compound; substituted aniline	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	2.03	1	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	2.02	1	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
clotrimazole [no description available]	2.03	1	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
4-cresol 4-cresol: RN given refers to parent cpd. p-cresol : A cresol that consists of toluene substituted by a hydroxy group at position 4. It is a metabolite of aromatic amino acid metabolism produced by intestinal microflora in humans and animals.	2.08	1	cresol	Escherichia coli metabolite; human metabolite; uremic toxin
cyclosporine cyclosporin A : A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.	2.59	2
damnacanthal damnacanthal: structure given in first source; isolated from the stem bark and roots of Morinda lucida; a selective inhibitor of p56(lck) tyrosine kinase activity	2.03	1	aldehyde; monohydroxyanthraquinone
dephostatin dephostatin: from Streptomyces sp. MJ742-NF5; structure given in first source	2	1
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	2.13	1	primary amine
r 59022 R 59022: diacylglycerol kinase inhibitor; structure given in first source; platelet activator factor antagonist	2.03	1	diarylmethane
diphenyleneiodonium diphenyleneiodonium: structure in first source; NADPH oxidase inhibitor. dibenziodolium : An organic cation that is fluorene in which the methylene group is replaced by a positively charged iodine.	2.47	2	organic cation
n(6),n(6)-dimethyladenine N(6),N(6)-dimethyladenine : A tertiary amine that is adenine substituted at N-6 by geminal methyl groups.	2.45	2	tertiary amine
ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.	2.03	1	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	2.01	1
profenamine profenamine: was heading 1972-94 (see under PHENOTHIAZINES 1972-90); use PHENOTHIAZINES to search ETHOPROPAZINE 1972-94. profenamine : A member of the class of phenothiazines that is phenothiazine in which the hydrogen attached to the nitrogen is substituted by a 2-(diethylamino)propyl group. An antimuscarinic, it is used as the hydrochloride for the symptomatic treatment of Parkinson's disease.	3.25	1	phenothiazines; tertiary amino compound	adrenergic antagonist; antidyskinesia agent; antiparkinson drug; histamine antagonist; muscarinic antagonist
carbonyl cyanide p-trifluoromethoxyphenylhydrazone Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.	2.17	1	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
fenbendazole Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.. fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.	2.89	3	aryl sulfide; benzimidazoles; carbamate ester	antinematodal drug
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	2.03	1	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.15	1	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.11	1	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	2	1	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
fpl 64176 FPL 64176: an activator of L-type calcium channels; structure given in first source. FPL 64176 : 1H-Pyrrole substituted at C-2 and -5 by methyl groups, at C-3 by methoxycarbonyl and at C-4 by a 2-benzylbenzoyl group.	2.31	1	carboxylic ester; pyrroles	calcium channel agonist
gemfibrozil [no description available]	2.03	1	aromatic ether	antilipemic drug
gö6983 [no description available]	4.36	19	indoles; maleimides
gw8510 GW8510: 3' substituted indolone as a scaffold for the development of neuroprotective drug; structure in first source	2.06	1
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide [no description available]	2.03	1	isoquinolines; sulfonamide
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide [no description available]	2.06	1	bromobenzenes; isoquinolines; olefinic compound; secondary amino compound; sulfonamide	EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
1-(5-isoquinolinesulfonyl)-2-methylpiperazine 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.	3.26	6	isoquinolines; N-sulfonylpiperazine	EC 2.7.11.13 (protein kinase C) inhibitor
ha 1004 N-(2-guanidinoethyl)-5-isoquinolinesulfonamide: structure given in first source	2.71	3	isoquinolines
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	3.29	6	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.89	3	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
harmaline Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.	2.03	1	harmala alkaloid	oneirogen
harmalol harmalol: inhibitor of rat liver microsomal UDP-glucuronyltransferase; RN given refers to parent cpd; structure. harmalol : A harmala alkaloid in which the harman skeleton is hydroxy-substituted at C-7 and has been reduced across the 3,4 bond.	2.03	1	harmala alkaloid	algal metabolite; EC 1.4.3.4 (monoamine oxidase) inhibitor
homochlorocyclizine homochlorocyclizine: RN given refers to parent cpd	2.89	3	diarylmethane
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	2.89	3	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
ic 261 [no description available]	2.03	1	indoles
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.06	1	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifenprodil ifenprodil: NMDA receptor antagonist	2.89	3	piperidines
indirubin-3'-monoxime indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.74	3
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
1-methyl-3-isobutylxanthine 1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.	2.02	1	3-isobutyl-1-methylxanthine
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	3.11	5	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
whi p154 WHI P154: an anti-leukemic agent; structure in first source	2.08	1
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone ZM39923: structure in first source	3.07	4	naphthalenes
1-(2-naphthalenyl)-2-propen-1-one [no description available]	2.03	1	naphthalenes
staurosporine aglycone staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor	3.26	6
nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).	3.14	5	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.89	3	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.03	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.89	3	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
beta-lapachone beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.	2.03	1	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite
lavendustin a lavendustin A: from Streptomyces griseolavendus; structure given in first source	2.03	1	aromatic amine
2-hydroxy-5-(2,5-dihydrobenzyl)aminobenzoic acid [no description available]	2.44	2	aromatic amine
letrozole [no description available]	2.03	1	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	2.43	2	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
ly 303511 LY 303511: inhibitor of phosphatidylinositol 3-kinase	2.08	1	N-arylpiperazine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	4.42	21	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	2.89	3	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mephenesin Mephenesin: A centrally acting muscle relaxant with a short duration of action.. 1-(2-methylphenyl)glycerol : A glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage.	2.89	3	aromatic ether; glycerol ether
nocodazole [no description available]	2.44	2	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
milrinone [no description available]	2.03	1	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
ml 7 ML-7 : An N-sulfonyldiazepane resullting from the formal condensation of 5-iodo-1-naphthylsulfonic acid with one of the nitrogens of 1,4-diazepane. It is a selective inhibitor of myosin light chain kinase (EC 2.7.11.18).	2.11	1	N-sulfonyldiazepane; organoiodine compound	EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
ml 9 [no description available]	2.03	1	naphthalenes; sulfonic acid derivative
molsidomine Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.. molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.	2.47	2	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide: calmodulin antagonist; structure given in first source. N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide : A sulfonamide that is 5-chloronaphthalene-2-sulfonamide in which one of the hydrogens of the nitrogen atom is substituted by a 4-aminobutyl group.	2.02	1	naphthalenes; organochlorine compound; primary amino compound; sulfonamide
activins Activins: Activins are produced in the pituitary, gonads, and other tissues. By acting locally, they stimulate pituitary FSH secretion and have diverse effects on cell differentiation and embryonic development. Activins are glycoproteins that are hetero- or homodimers of INHIBIN-BETA SUBUNITS.	2.08	1
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	4.32	5	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	2.03	1	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.01	1	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	2	1	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
npc 15437 NPC 15437: interacts with th C1 doamin of protein kinase C	2.03	1
nu6102 NU6102: structure in first source	2.03	1
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.45	2	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
oxibendazole oxibendazole: structure	2.89	3	benzimidazoles; carbamate ester
oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).	2.44	2	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine 4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine: a 5-HT(1A) ligand; structure in first source	2.89	3
patulin Patulin: 4-Hydroxy-4H-furo(3,2-c)pyran-2(6H)-one. A mycotoxin produced by several species of Aspergillus and Penicillium. It is found in unfermented apple and grape juice and field crops. It has antibiotic properties and has been shown to be carcinogenic and mutagenic and causes chromosome damage in biological systems.. patulin : A furopyran and lactone that is (2H-pyran-3(6H)-ylidene)acetic acid which is substituted by hydroxy groups at positions 2 and 4 and in which the hydroxy group at position 4 has condensed with the carboxy group to give the corresponding bicyclic lactone. A mycotoxin produced by several species of Aspergillus and Penicillium, it has antibiotic properties but has been shown to be carcinogenic and mutagenic.	2.03	1	furopyran; gamma-lactone; lactol	antimicrobial agent; Aspergillus metabolite; carcinogenic agent; mutagen; mycotoxin; Penicillium metabolite
pd 153035 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source. PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.	2.44	2	aromatic amine; aromatic ether; bromobenzenes; quinazolines; secondary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
pd 158780 [no description available]	2.46	2	aromatic amine; bromobenzenes; diamine; pyridopyrimidine; secondary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
pd 169316 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor	2.46	2	imidazoles
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	4.97	37	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pentoxifylline [no description available]	1.99	1	oxopurine
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	4.2	4	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
3,3',4,5'-tetrahydroxystilbene [no description available]	2.06	1	stilbenoid
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	2.89	3	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
pinacidil Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)	2.03	1	pyridines
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.03	1	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	2.71	3	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
1-NA-PP1 [no description available]	2.44	2	pyrazolopyrimidine	tyrosine kinase inhibitor
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	3.67	9	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine [no description available]	2.08	1	pyrazoles; ring assembly
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	2	1	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
proadifen Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.	2.02	1	diarylmethane
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.42	2	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
quetiapine [no description available]	2.03	1	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one [no description available]	2.59	2	indoles
raloxifene raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.	2.03	1	1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	2.03	1	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
ro 31-8220 Ro 31-8220: a protein kinase C inhibitor	11.06	37	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
rofecoxib [no description available]	2.03	1	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
rolipram [no description available]	2.03	1	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
ropinirole [no description available]	2.89	3	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist
sb 220025 SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.	2.75	3	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 239063 SB 239063: structure in first source. SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.	2.45	2	imidazoles
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	3.29	6	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
linsidomine linsidomine: RN given refers to parent cpd; structure	2.47	2	morpholines
sk&f 86002 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase	2.08	1	imidazoles
imatinib [no description available]	2.73	3	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.08	4	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	1.99	1	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.06	1	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.03	1	diarylmethane
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	2.03	1	phthalimides; piperidones
thiethylperazine Thiethylperazine: A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457). thiethylperazine : A member of the class of phenothiazines that is perazine substituted by a ethylsulfanyl group at position 2.	3.25	1	N-methylpiperazine; phenothiazines	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
thioridazine Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.	3.25	1	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
thymeleatoxin thymeleatoxin: causes translocation & down-regulation of multiple protein kinase C isozymes	3.51	8
tiopronin Tiopronin: Sulfhydryl acylated derivative of GLYCINE.	2	1	N-acyl-amino acid
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate: intracellular calcium antagonist; RN given refers to parent cpd	2.44	2	trihydroxybenzoic acid
2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine [no description available]	2.59	2	stilbenoid
trifluperidol Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)	2.15	1	aromatic ketone
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.94	4	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
whi p180 [no description available]	2.03	1
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.	2.89	3	aromatic primary alcohol; furans; indazoles	antineoplastic agent; apoptosis inducer; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
zinc chloride zinc chloride: RN given refers to parent cpd. zinc dichloride : A compound of zinc and chloride ions in the ratio 1:2. It exists in four crystalline forms, in each of which the Zn(2+) ions are trigonal planar coordinated to four chloride ions.	2.06	1	inorganic chloride; zinc molecular entity	astringent; disinfectant; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; Lewis acid
zm 336372 N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source	2.72	3	benzamides
zonisamide Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.	2.03	1	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
zotepine zotepine: structure	2.89	3	dibenzothiepine; tertiary amino compound	alpha-adrenergic drug; second generation antipsychotic; serotonergic drug
corticosterone [no description available]	2.41	2	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
thymidine [no description available]	2.46	2	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
carbachol Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.	3.4	7	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
aldosterone [no description available]	2.44	2	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
dehydroepiandrosterone Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.	2	1	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
dichlororibofuranosylbenzimidazole Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.	2.03	1
azauridine Azauridine: A triazine nucleoside used as an antineoplastic antimetabolite. It interferes with pyrimidine biosynthesis thereby preventing formation of cellular nucleic acids. As the triacetate, it is also effective as an antipsoriatic.	3.25	1	N-glycosyl-1,2,4-triazine	antimetabolite; antineoplastic agent; drug metabolite
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	1.99	1	pilocarpine	antiglaucoma drug
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	3.91	12	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.73	3	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2	1	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.41	2	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	2.71	3	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	2.43	2	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
phenylethyl alcohol Phenylethyl Alcohol: An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery.. 2-phenylethanol : A primary alcohol that is ethanol substituted by a phenyl group at position 2.	2.05	1	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	3.51	8	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
methoxamine Methoxamine: An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.. methoxamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group and the phenyl ring is 2- and 5-substituted with methoxy groups. It is an antihypotensive agent (pressor), an agonist acting directly at alpha-adrenoceptors with selectivity for the alpha-1 adrenoceptor subtype similar to phenylephrine .	1.99	1	amphetamines	alpha-adrenergic agonist; antihypotensive agent
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	2.01	1	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.05	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
uridine triphosphate Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.	2.03	1	pyrimidine ribonucleoside 5'-triphosphate; uridine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.08	1	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
desoxycorticosterone Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE	2.01	1	20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	3.05	4	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	3.39	7	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
egtazic acid Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.. ethylene glycol bis(2-aminoethyl)tetraacetic acid : A diether that is ethylene glycol in which the hydrogens of the hydroxy groups have been replaced by 2-[bis(carboxymethyl)amino]ethyl group respectively.	3.96	13	diether; tertiary amino compound; tetracarboxylic acid	chelator
fluocinolone acetonide Fluocinolone Acetonide: A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluocinolone acetonide : A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders.	2	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; glucocorticoid; organic heteropentacyclic compound; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
benziodarone benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)	2.89	3	aromatic ketone
mannitol [no description available]	2	1	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine [no description available]	2.02	1	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
threonine Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.	2.73	3	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.47	2	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	2.44	2	amino sulfonic acid; bile acid taurine conjugate	human metabolite
cyclizine Cyclizine: A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935). cyclizine : An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.	2.21	1	N-alkylpiperazine	antiemetic; central nervous system depressant; cholinergic antagonist; H1-receptor antagonist; local anaesthetic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.48	2	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2	1	xanthene
1,3-ditolylguanidine 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain	2.01	1	toluenes
trehalose alpha,alpha-trehalose : A trehalose in which both glucose residues have alpha-configuration at the anomeric carbon.	2.89	3	trehalose	Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
triclocarban triclocarban: bacteriostat; antiseptic in soaps & other cleansing solns; germicide; structure. triclocarban : A member of the class of phenylureas that is urea substituted by a 4-chlorophenyl group and a 3,4-dichlorophenyl group at positions 1 and 3 respectively.	2.89	3	dichlorobenzene; monochlorobenzenes; phenylureas	antimicrobial agent; antiseptic drug; disinfectant; environmental contaminant; xenobiotic
1,3-diphenylurea 1,3-diphenylurea : A member of the class of phenylureas that is urea in which one of the hydrogens of each amino group is replaced by a phenyl group. It is present in coconut milk (Cocos nucifera).	2.06	1	phenylureas	cytokinin; plant metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	4.93	11	pyrrole; secondary amine
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	2.02	1	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	3.14	5	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
1,4-naphthoquinone naphthoquinone : A polycyclic aromatic ketone metabolite of naphthalene.. 1,4-naphthoquinone : The parent structure of the family of 1,4-naphthoquinones, in which the oxo groups of the quinone moiety are at positions 1 and 4 of the naphthalene ring. Derivatives have pharmacological properties.	2.03	1	1,4-naphthoquinones
monobutyl phthalate monobutyl phthalate: RN given refers to parent cpd	3.25	1	phthalic acid monoester
4-tert-octylphenol 4-tert-octylphenol: structure given in first source	2.89	3	alkylbenzene
2-chloroadenosine 5-chloroformycin A: structure given in first source	2.05	1	purine nucleoside
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	2.02	1	catechin	antioxidant; plant metabolite
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.97	4	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	2.17	1	1,3-benzoxazoles; mancude organic heterobicyclic parent
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.21	1	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
ethamivan ethamivan: minor descriptor (65-72); major descriptor (73-86); on-line search BENZAMIDES (66-86); INDEX MEDICUS search BENZAMIDES (65-72); ETHAMIVAN (73-86). etamivan : Phenol substituted at C-2 and C-4 by a methoxy group and an N,N-diethylaminocarbonyl group respectively. A respiratory stimulant drug related to nikethamide, it has now fallen largely into disuse.	2.89	3	methoxybenzenes; phenols
evans blue Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.. Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.	2.03	1	organic sodium salt	fluorochrome; histological dye; sodium channel blocker; teratogenic agent
methysergide Methysergide: An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.. methysergide : A synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD and used prophylactically to reduce the frequency and intensity of severe vascular headaches.	2.89	3	ergoline alkaloid
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.89	3	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	2.89	3	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	2.02	1	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.02	1	dialdehyde	biomarker
neutral red Neutral Red: A vital dye used as an indicator and biological stain. Various adverse effects have been observed in biological systems.. neutral red : A hydrochloride obtained by combining the free base of neutral red with one equivalent of hydrochloric acid. Neutral red acts as a pH indicator, changing from red to yellow between pH 6.8 and 8.0.	2	1	hydrochloride	acid-base indicator; dye; two-colour indicator
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.74	3	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
2-piperidone 2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.	2.02	1	delta-lactam; piperidones	EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
etonitazene etonitazene: was heading 1979-94 (see under BENZIMIDAZOLES 1979-90); ETONITAZIN was see ETONITAZENE 1979-94; use BENZIMIDAZOLES to search ETONITAZENE 1979-94; narcotic analgesic similar to morphine in action; used mainly to study narcotic habituation, tolerance, and withdrawal in laboratory animals	2.89	3
methdilazine methdilazine : A phenothiazine substituted on nitrogen by a (1-methylpyrrolidin-3-yl)methyl group; a first-generation antihistamine with anticholinergic properties.	3.25	1	N-alkylpyrrolidine; phenothiazines	antipruritic drug; cholinergic antagonist; histamine antagonist
durapatite Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).	2	1
arsenic trioxide Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.	2.45	2
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	2.07	1	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
clothiapine clothiapine: was heading 1975-94 (was see under DIBENZOTHIAZEPINES 1975-90); CLOTIAPINE was see CLOTHIAPINE 1978-94; use DIBENZOTHIAZEPINES to search CLOTHIAPINE 1975-94; antipsychotic similar to clozapine	2.89	3	dibenzothiazepine
benperidol Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)	2.89	3	aromatic ketone
7-hydroxychlorpromazine 7-hydroxychlorpromazine: RN given refers to parent cpd	2.89	3	phenothiazines
azetidyl-2-carboxylic acid azetidyl-2-carboxylic acid: a proline analog (with 4-membered ring in place of 5); a toxic non-protein amino acid that is misincorporated into protein in place of proline; induces nonfunctional heat-shock proteins; inhibits acquired thermotolerance; RN given refers to (L)-isomer; found in beets and Liliaceae. (S)-azetidine-2-carboxylic acid : The (S)-enantiomer of azetidine-2-carboxylic acid.. azetidinecarboxylic acid : A member of the class of azetidines that is azetidine substituted by at least one carboxy group at unspecified position.	2.03	1	azetidine-2-carboxylic acid
fluorescein-5-isothiocyanate Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.	2.02	1	fluorescein isothiocyanate
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	2.31	1	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
helenalin helenalin: toxic principle of Helenium microcephalum (smallhead sneezeweed); structure. helenalin : A sesquiterpene lactone that is 3,3a,4,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione substituted by a hydroxy group at position 4, methyl groups at positions 4a and 8 and a methylidene group at position 3 (the 3aS,4S,4aR,7aR,8R,9aR stereoisomer).. NF-kappaB inhibitor : An inhibitor of NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells), a protein complex involved in the transcription of DNA.	2.03	1	cyclic ketone; gamma-lactone; organic heterotricyclic compound; secondary alcohol; sesquiterpene lactone	anti-inflammatory agent; antineoplastic agent; metabolite; plant metabolite
lanthanum [no description available]	2.02	1	f-block element atom; lanthanoid atom; scandium group element atom
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	2.7	3	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
cadmium Cadmium: An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.. elemental cadmium : An element in the zinc group of the periodic table with atomic number 48, atomic mass 112, M.P. 321degreeC, and B.P. 765degreeC). An odourless, tasteless, and highly poisonous soft, ductile, lustrous metal with electropositive properties. It has eight stable isotopes: (106)Cd, (108)Cd,(110)Cd, (111)Cd, (112)Cd, (113)Cd, (114)Cd and (116)Cd, with (112)Cd and (114)Cd being the most common.	2.44	2	cadmium molecular entity; zinc group element atom
galactosamine 2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.	2.06	1	D-galactosamine; primary amino compound	toxin
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	3.03	4	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
ferrous sulfate ferrous sulfate: Ferro-Gradumet is ferrous sulfate in controlled release form; RN given refers to Fe(+2)[1:1] salt. iron(2+) sulfate (anhydrous) : A compound of iron and sulfate in which the ratio of iron(2+) to sulfate ions is 1:1. Various hydrates occur naturally - most commonly the heptahydrate, which loses water to form the tetrahydrate at 57degreeC and the monohydrate at 65degreeC.	2.02	1	iron molecular entity; metal sulfate	reducing agent
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.03	1	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
thenalidine thenalidine: antihistaminic, antipruritic; RN in Chemline for thenalidine calcium: 67250-62-8; structure	2.89	3	dialkylarylamine; tertiary amino compound
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	6.05	112	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
deslanoside Deslanoside: Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.. deslanoside : A cardenolide glycoside that is lanatoside C with the acetoxy group replaced by a hydroxy group.	3.25	1	12beta-hydroxy steroid; 14beta-hydroxy steroid; cardenolide glycoside; tetrasaccharide derivative	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; metabolite
phosphotyrosine Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.. O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.	3.12	5	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine	Escherichia coli metabolite; immunogen
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	2.89	3	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.71	3	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
dexchlorpheniramine dexchlorpheniramine: RN given refers to parent cpd(S)-isomer	2.89	3	chlorphenamine
dv 1006 [no description available]	2.89	3
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.73	3	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2.43	2	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
substance p [no description available]	1.99	1	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
dobutamine Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.	2.03	1	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
propylbenzilylcholine mustard Propylbenzilylcholine Mustard: An analog of benzilylcholine mustard. It is an alkylating nitrogen mustard analog that binds specifically and irreversibly to cholinergic muscarinic receptors and is used as an affinity label to isolate and study the receptors.	1.99	1
ribavirin Rebetron: Rebetron is tradename	3.25	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
phorbol 12,13-dibutyrate Phorbol 12,13-Dibutyrate: A phorbol ester found in CROTON OIL which, in addition to being a potent skin tumor promoter, is also an effective activator of calcium-activated, phospholipid-dependent protein kinase (protein kinase C). Due to its activation of this enzyme, phorbol 12,13-dibutyrate profoundly affects many different biological systems.	4.09	15	butyrate ester; phorbol ester; tertiary alpha-hydroxy ketone
climbazole 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one : A ketone that is butan-2-one substituted by a 4-chlorophenoxy and a 1H-imidazol-1-yl group at position 1 and 2 methyl groups at position 3.	2.89	3	aromatic ether; hemiaminal ether; imidazoles; ketone; monochlorobenzenes
triadimenol triadimenol : A member of the class of triazoles that is 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butane-1,2-diol substituted at position O1 by a 4-chlorophenyl group. A fungicide for cereals, beet and brassicas used to control a range of diseases including powdery mildew, rusts, bunts and smuts.	2.89	3	aromatic ether; conazole fungicide; hemiaminal ether; monochlorobenzenes; secondary alcohol; triazole fungicide	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; xenobiotic metabolite
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	3.25	1	benzamides; carboxylic ester
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	2.03	1	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
staurosporine [no description available]	2.96	4	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
bw-755c 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine: A dual inhibitor of both cyclooxygenase and lipoxygenase pathways. It exerts an anti-inflammatory effect by inhibiting the formation of prostaglandins and leukotrienes. The drug also enhances pulmonary hypoxic vasoconstriction and has a protective effect after myocardial ischemia.	2	1
colforsin Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.	2.93	4	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
amonafide xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor	2.89	3	isoquinolines
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	2.03	1	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	2.89	3	aminopyridine
chaetochromin chaetochromin: from Chaetomium spp.; RN given refers to chaetochromin A	2.89	3
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.89	3	aromatic ketone
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.03	1	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
quinpirole Quinpirole: A dopamine D2/D3 receptor agonist.. quinpirole : A pyrazoloquinoline that is (4aR,8aR)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]quinoline substituted by a propyl group at position 5. It acts as a dopamine agonist.	2.48	2	pyrazoloquinoline	dopamine agonist
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	2.03	1	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
antineoplaston a10 antineoplaston A10: peptide analogue isolated from human urine	2.02	1
fura-2 Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.	2.4	2
aromasil [no description available]	2.03	1	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	2.89	3	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
atorvastatin [no description available]	2.03	1	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
ziprasidone ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.	2.03	1	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.73	3	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
vanadates Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects.. vanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms.	2	1	trivalent inorganic anion; vanadium oxoanion	EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.02	1	D-glucopyranose	epitope; mouse metabolite
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	2.03	1	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
norharman norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.	2.06	1	beta-carbolines; mancude organic heterotricyclic parent	fungal metabolite; marine metabolite
arctigenin arctigenin: precursor to catechols; in many plants	2.03	1	lignan
baicalin [no description available]	3.25	1	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.56	2	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
triciribine [no description available]	2.08	1	nucleoside analogue	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
aloxistatin aloxistatin: a membrane-permeable cysteine protease inhibitor. aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide.	2.21	1	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor
indocate [no description available]	2.89	3
azelnidipine azelnidipine: structure given in first source	2.03	1	isopropyl ester
methacycline [no description available]	2.01	1	1,2-diglyceride
N(4)-acetylsulfathiazole N(4)-acetylsulfathiazole : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a 1,3-thiazol-2-yl group at the nitrogen atom. It is a metabolite of sulfathiazole.	2.89	3	1,3-thiazoles; acetamides; sulfonamide	marine xenobiotic metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2	1	1,2,3-triazole
cyclizine hydrochloride [no description available]	2.59	2
2,3-trimethylene-4-quinazolone 2,3-trimethylene-4-quinazolone: structure in first source	2.89	3	quinazolines
sertraline Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.	2.03	1	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
1,3-dimethyluric acid 1,3-dimethyluric acid : An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trionesubstituted by methyl groups at N-1 and N-3.	2.89	3	oxopurine	metabolite
danofloxacin [no description available]	2.89	3	quinolines
nitrefazole [no description available]	2.89	3	imidazoles
methotrimeprazine Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.	2.89	3	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
phorbol-12,13-diacetate phorbol-12,13-diacetate: RN given refers to (1aR-(1a alpha,1b beta,4a beta,7a alpha,7b alpha,8 alpha,9 beta,9a alpha))-isomer	2.03	1
honokiol [no description available]	2.89	3	biphenyls
chelerythrine chloride [no description available]	2.03	1
9-methoxyellipticine 9-methoxyellipticine: RN given refers to parent cpd	2.89	3
3-aminophenoxazone 3-aminophenoxazone: also inhibits sulfatase; structure	2.89	3	phenoxazine
3-deazaneplanocin 3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist	2.89	3
fascaplysine fascaplysine: from tropic sea sponges	2.03	1
LSM-4272 [no description available]	2.08	1	beta-carbolines
tryptanthrine tryptanthrine: minor constituent of traditional Chinese medicine qing dai	2.89	3	alkaloid antibiotic; organic heterotetracyclic compound; organonitrogen heterocyclic compound
2-chlorodiazepam [no description available]	2.89	3
Polycartine B [no description available]	2.89	3	phenazines
rosiglitazone [no description available]	2.42	2	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
aminoquinuride dihydrochloride [no description available]	2.89	3
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.45	2	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
alpha-curcumene alpha-curcumene: active priniciple in essential oils of Curcuma xanthorrhiza. alpha-curcumene : A sesquiterpene that is 2-methyl-2-heptene in which one of the hydrogens at position 6 is substituted by a p-tolyl group.	3.25	1	sesquiterpene
thioproperazine mesylate [no description available]	2.89	3	phenothiazines
n(6)-(delta(2)-isopentenyl)adenine N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group.	2.89	3	6-isopentenylaminopurine	cytokinin
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.05	1
4-methyl-N-(phenylmethyl)benzenesulfonamide [no description available]	2.89	3	sulfonamide
eupatorin eupatorin: a flavonoid from the East Asian medicinal plant Orthosiphon spicatus; prevents oxidative inactivation of 15-lipoxygenase; structure given in first source. eupatorin : A trimethoxyflavone that is 6-hydroxyluteolin in which the phenolic hydogens at positions 4', 6 and 7 have been replaced by methyl groups.	2.06	1	dihydroxyflavone; polyphenol; trimethoxyflavone	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; Brassica napus metabolite; calcium channel blocker; P450 inhibitor; vasodilator agent
5-iodotubercidin 7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase	2.03	1	organoiodine compound
zpck ZPCK: alkylates histidine residue at active center of bovine chymotrypsin	2.63	2
phorbolol myristate acetate [no description available]	2.01	1
3,7,11,15-tetramethyl-1-hexadecanol 3,7,11,15-tetramethyl-1-hexadecanol: intermediate in conversion of phytol to phytanic acid	3.25	1
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	2.45	2	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid: structure in first source	2	1	polyamino carboxylic acid; tetracarboxylic acid	chelator
u 73122 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione: structure given in first source. U-73122 : An aza-steroid that is 3-O-methyl-17beta-estradiol in which the 17beta-hydroxy group is replaced by a 6-(maleimid-1-yl)hexylamino group. An inibitor of phospholipase C.	4.23	17	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
sr141716 [no description available]	2.89	3	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
diacetyldichlorofluorescein diacetyldichlorofluorescein: stable storage form of dichlorofluorescein	2.01	1
indolactam v indolactam V: only the (-)-isomer of indolactam V showed carcinogenic activity; structure given in first source	2.02	1	indoles
paxilline paxilline: structure given in first source; RN given refers to (2R-(2alpha,4bbeta,6aalpha,12bbeta,12calpha,14abeta))-isomer. paxilline : An indole diterpene alkaloid with formula C27H33NO4 isolated from Penicillium paxilli. It is a potent inhibitor of large conductance Ca2(+)- and voltage-activated K(+) (BK)-type channels.	2.45	2	diterpene alkaloid; enone; organic heterohexacyclic compound; terpenoid indole alkaloid; tertiary alcohol	anticonvulsant; Aspergillus metabolite; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; genotoxin; geroprotector; mycotoxin; Penicillium metabolite; potassium channel blocker
(6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide [no description available]	2.59	2	aromatic ketone
cgp 35348 CGP 35348: antagonizes both GABA-A and GABA-B receptors	2.07	1
methoctramine methoctramine: structure given in first source. methoctramine : A tetramine that is N,N'-bis(6-aminohexyl)octane-1,8-diamine where the primary amino groups both carry 2-methoxybenzyl substituents.. methoctramine tetrahydrochloride : A hydrochloride obtained by combining methoctramine with four molar equivalents of hydrochloric acid.	2.02	1	hydrochloride	muscarinic antagonist
phorbol-12-myristate [no description available]	2.42	2
12-deoxyphorbol 13-isobutyrate 12-deoxyphorbol 13-isobutyrate: RN given refers to (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9aalpha))-isomer	2.01	1
fingolimod fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.	2.89	3	aminodiol; primary amino compound	antineoplastic agent; CB1 receptor antagonist; immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
tesmilifene [no description available]	2.89	3	diarylmethane
sch 28080 Sch 28080: not related structurally to other known anti-ulcer agents; inhibits histamine-stimulated gastric secretion; prevents gastric lesions induced by aspirin, indomethacin & ethanol	2.07	1	imidazopyridine
kt 5823 KT 5823: indolocarbazole; activates human neutrophils & fails to inhibit cGMP-dependent protein kinase phosphorylation of vimentin. KT 5823 : An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of methyl (3R)-3-methoxy-2-methyltetrahydrofuran-3-carboxylate (the 2S,3R,5R product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1-methyl-1,5-dihydro-2H-pyrrol-2-one.	2	1	gamma-lactam; hemiaminal; indolocarbazole; methyl ester; organic heterooctacyclic compound	EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	2	1
tadalafil [no description available]	2.03	1	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
indolo(3,2-b)carbazole indolo(3,2-b)carbazole: potent inducer of cytochrome P-4501A1-dependent monooxygenase	2	1
thromboxanes thromboxane : A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.	2	1
3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate: purinergic receptors agonist; structure given in first source	2.01	1	purine ribonucleoside triphosphate
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride: structure given in first source; a sigma receptor ligand	2.01	1
valdecoxib [no description available]	2.03	1	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
egta acetoxymethyl ester EGTA acetoxymethyl ester: membrane-permeable form of EGTA	2.02	1
methylthio-adp [no description available]	2	1
sr 27897 SR 27897: structure given in first source; a CCK(A) receptor antagonist	2.89	3	indolyl carboxylic acid
peroxynitrous acid Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES).	2.48	2	nitrogen oxoacid
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.03	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.45	2	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer)	2.89	3	leucine derivative
norketamine norketamine: metabolite of ketamine; RN given refers to cpd without isomeric designation	2.89	3	organochlorine compound
2-chloro-n(6)cyclopentyladenosine 2-chloro-N(6)cyclopentyladenosine: highly selective agonist at A1 adenosine receptors	2.08	1
e 64 E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)	2.05	1	dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion	antimalarial; antiparasitic agent; protease inhibitor
indatraline indatraline: RN given for (trans)-isomer; structure in first source	2.63	2	indanes
methotrexate [no description available]	2.89	3	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
ro 32-0432 [no description available]	4.03	4
salvinorin a salvinorin A: from the herb, Salvia divinorum	2.21	1	organic heterotricyclic compound; organooxygen compound	metabolite; oneirogen
cki 7 N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide: casein kinase I inhibitor; structure given in first source. N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide : A member of the class of isoquinolines that is isoquinoline-8-sulfonamide which is substituted by chlorine at position 5 and in which the sulfonamide nitrogen is substituted by a 2-aminoethyl group. It is an inhibitor of casein kinase I.	2.03	1	isoquinolines; organochlorine compound; primary amino compound; sulfonamide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
1-naphthylacetylspermine [no description available]	2.03	1	naphthalenes
umifenovir umifenovir: an antiviral agent	3.25	1	indolyl carboxylic acid
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide 4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide: increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol	2.89	3
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide: binds with high affinity to glial mitochondrial diazepam binding inhibitor receptors & increases mitochondrial steroidogenesis	2.89	3	phenylindole
ns 1608 NS 1608: a BK(Ca) channel opener	2.06	1	ureas
l 741626 3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole: structure in first source	2.89	3	piperidines
8-chloroadenosine 8-chloroadenosine: active metabolite of 8-chloro-cyclic adenosine 3',5'-monophosphate	2.05	1
dx 8951 [no description available]	2.89	3	pyranoindolizinoquinoline
vatalanib [no description available]	2.45	2	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
ruboxistaurin ruboxistaurin: inhibits protein kinase C beta; structure in first source	4.51	7
birb 796 [no description available]	2.45	2	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.02	1	oxygen hydride; oxygen radical; reactive oxygen species
nps-568 N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine: NPS-568 is the ((R), HCl salt)-isomer; calcimimetic compound and calcium-sensing receptor agonist	2.03	1
tipifarnib [no description available]	2.89	3	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	3.33	6	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
methylselenic acid methylseleninic acid : An organoselenium compound that is seleninic acid in which the hydrogen attached to selenium is replaced by a methyl group.	2.1	1	one-carbon compound; organoselenium compound	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor; human xenobiotic metabolite
tanshinone ii a tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source	2.1	1	abietane diterpenoid
avasimibe [no description available]	2.89	3	monoterpenoid
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	2.1	1	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	3.73	10	amino acid zwitterion; angiotensin II	human metabolite
sb 203580 [no description available]	4.38	20	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
sb 216763 [no description available]	2.45	2	indoles; maleimides
enzastaurin [no description available]	2.04	1	indoles; maleimides
zm 241385 ZM 241385: a high affinity radioligand selective for the A2a adenosine receptor	2	1	diamino-1,3,5-triazine
erlotinib [no description available]	2.45	2	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
erlotinib hydrochloride [no description available]	2.08	1	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
antalarmin antalarmin : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidin-4-amine which is substituted by methyl groups at positions 2, 5, and 6, by a mesityl group at position 7, and in which the amino substituent at position 4 has been substituted by ethyl and butyl groups. It is an antagonist of corticotropin-releasing factor 1 (CRF-1) receptors (Ki = 1 nM).	2.07	1	pyrrolopyrimidine; tertiary amino compound	corticotropin-releasing factor receptor antagonist
l 163191 [no description available]	2.89	3
dizocilpine [no description available]	2.89	3	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
s-benzylcysteine [no description available]	2.89	3	S-aryl-L-cysteine zwitterion
chelidonine chelidonine: benzophenanthridine derived from scoulerine from Chelidonium majus; RN given refers to parent cpd (chelidonine, (5bR-(5balpha,6beta,12alpha))-isomer)	2.89	3	alkaloid antibiotic; alkaloid fundamental parent; benzophenanthridine alkaloid
orantinib [no description available]	2.06	1	monocarboxylic acid; oxindoles; pyrroles	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
lapatinib [no description available]	3.06	4	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
sorafenib [no description available]	2.73	3	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
roxindole [no description available]	2.89	3	indoles	alpha-adrenergic antagonist; serotonergic drug
conidendrin [no description available]	2.89	3
Porfiromycine [no description available]	2.89	3	mitomycin
anisomycin Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.	2.46	2	monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic	anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.1	1
nsc 95397 [no description available]	2.89	3	1,4-naphthoquinones
4-methyl-2-quinazolinamine 4-methyl-2-quinazolinamine: from Streptomyces of TCM plant; structure in first source	2.89	3
2-glycineamide-5-chlorophenyl-2-pyrryl ketone [no description available]	2.89	3
t 1105 T 1105: has antiviral activity; structure in first source	3.25	1
wortmannin [no description available]	4.46	22	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
niguldipine hydrochloride [no description available]	2.63	2
paullone paullone: structure in first source. paullone : An indolobenzazepine that is 5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine carrying an oxo substituent at position 6.	2.03	1	indolobenzazepine; lactam	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
2,5-bis(5-hydroxymethyl-2-thienyl)furan [no description available]	2.89	3	thiophenes
tris(2-pyridylmethyl)amine tris(2-pyridylmethyl)amine: structure in first source	2.02	1
taurochenodeoxycholic acid Taurochenodeoxycholic Acid: A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic.. taurochenodeoxycholate : An organosulfonate oxoanion that is the conjugate base of taurochenodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. taurochenodeoxycholic acid : A bile acid taurine conjugate of chenodeoxycholic acid.	2.04	1	bile acid taurine conjugate	human metabolite; mouse metabolite
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.89	3	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
bardoxolone methyl methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source	2.21	1	cyclohexenones
5-iodoindirubin-3'-monoxime 5-iodoindirubin-3'-monoxime: inhibits GSK-3beta	2.03	1
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	2.03	1
leupeptins Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.	2.41	2
Destruxin B [no description available]	2.89	3	cyclodepsipeptide
lithium chloride Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.	2.11	1	inorganic chloride; lithium salt	antimanic drug; geroprotector
2H-pyrazolo[4,3-b]quinoxalin-3-amine [no description available]	2.46	2	quinoxaline derivative
bradykinin [no description available]	2.71	3	oligopeptide	human blood serum metabolite; vasodilator agent
elastin [no description available]	2.01	1	oligopeptide
naringenin (S)-naringenin : The (S)-enantiomer of naringenin.	3.25	1	(2S)-flavan-4-one; naringenin	expectorant; plant metabolite
epiglucan epiglucan: a highly side-chain/branched alkali-insoluble cell wall glucan from fungus such as Epicoccum nigrum, Botrytis cinerea, ascomycetes & basidiomycetes; also isolated S-4001 from Lei Wan (polyporus mylitiae), HA-beta-glucan from mushroom Pleutotus ostreatus (Fr.) Quel., and translam from seaweed Laminaria cichorioides; with commercially important functional properties including emulsification and friction reduction.	2.03	1
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	2.42	2	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
laminaran beta-1,3-glucan: component of fungal cell walls; also used as antitumor polysaccharide; unspecified D usually means BETA-GLUCANS; beta-1,3-D-glucan is also available; glucan phosphate is also available; biosynthesis is inhibited by echinocandins (cyclic hexapeptides). laminarin : A polysaccharide composed of beta-(1->3)-linked glucose residues containing sporadic beta-(1->6)-linkages as branch points or inter-residue linkages and 2-3% D-mannitol at some reducing termini.	2.03	1
tosylphenylalanyl chloromethyl ketone Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.	2.89	3	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor
nitroarginine Nitroarginine: An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6). N(gamma)-nitro-L-arginine : An L-arginine derivative that is L-arginine in which the terminal nitrogen of the guanidyl group is replaced by a nitro group.	2.03	1	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid
adenosine 5'-o-(3-thiotriphosphate) adenosine 5'-O-(3-thiotriphosphate): RN given refers to cpd with unspecified locant for thio group; see also records for 1-thio & 2-thio-isomers. adenosine 5'-[gamma-thio]triphosphate : A nucleoside triphosphate analogue that is ATP in which one of the oxygens attached to 3-phosphate group is replaced by sulfur.	2.03	1	nucleoside triphosphate analogue
cortodoxone Cortodoxone: 17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.. 11-deoxycortisol : A deoxycortisol that is cortisol in which the hydroxy group at position 11 has been replaced by a hydrogen.	2.01	1	deoxycortisol; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
ryanodine Ryanodine: A methylpyrrole-carboxylate from RYANIA that disrupts the RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL to modify CALCIUM release from SARCOPLASMIC RETICULUM resulting in alteration of MUSCLE CONTRACTION. It was previously used in INSECTICIDES. It is used experimentally in conjunction with THAPSIGARGIN and other inhibitors of CALCIUM ATPASE uptake of calcium into SARCOPLASMIC RETICULUM.. ryanodine : An insecticide alkaloid isolated from South American plant Ryania speciosa.	2	1
ingenol [no description available]	2.02	1	cyclic terpene ketone; tetracyclic diterpenoid
acetylleucyl-leucyl-norleucinal acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.	2.43	2	aldehyde; tripeptide	cysteine protease inhibitor
n-formylmethionine leucyl-phenylalanine N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.	2.68	3	tripeptide
sodium arsenite sodium arsenite : An inoganic sodium salt with formula with formula NaAsO2.	2.03	1	arsenic molecular entity; inorganic sodium salt	antibacterial agent; antifungal agent; antineoplastic agent; carcinogenic agent; herbicide; insecticide; rodenticide
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.03	1	cyclodextrin
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	3.31	6	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.94	4	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	2.93	4	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.05	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
cerivastatin cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.	2.03	1	dihydroxy monocarboxylic acid; pyridines; statin (synthetic)
rosuvastatin rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).	2.03	1	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	3.82	11	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	3.25	1	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
hts 466284 HTS 466284: a TGFbeta-RI inhibitor; structure in first source	2.08	1	pyrazoles; pyridines; quinolines	TGFbeta receptor antagonist
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source	2.97	4
y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.	3.91	12	aromatic amide
h 1152 (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane : A member of the class of isoquinolines that is the sulfonamide formed by the formal condensation of the sulfo group of 4-methylisoquinoline-5-sulfonic acid with the 1-amino group of (S)-2-methyl-1,4-diazepane.	2.73	3	isoquinolines; N-sulfonyldiazepane	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
epothilone a Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).	2.03	1	epothilone; epoxide	antineoplastic agent; metabolite; microtubule-stabilising agent; tubulin modulator
7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine [no description available]	2.46	2
6-bromoindirubin-3'-oxime 6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.46	2
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	4.04	14	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
12-deoxyphorbol 13-acetate [no description available]	3.25	1	phorbol ester	metabolite
laminaran laminaran: beta-1,3-glucan	2.03	1
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.74	3	purvalanol
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.43	2	actinomycin	mutagen
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.04	1	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
sitafloxacin [no description available]	2.21	1	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.42	2	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione [no description available]	2.46	2	aminotoluene
favipiravir favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.	3.25	1	hydroxypyrazine; organofluorine compound; primary carboxamide	anticoronaviral agent; antiviral drug; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	2.89	3
evp 4593 EVP 4593: an NF-kappaB pathway inhibitor; structure in first source	2.08	1
jp-1302 [no description available]	2.89	3
bromochloroacetic acid Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.. bromochloroacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by bromine while a second is replaced by chlorine. A low-melting (27.5-31.5degreeC), hygroscopic crystalline solid, it can be formed during the disinfection (by chlorination) of water that contains bromide ions and organic matter, so can occur in drinking water as a byproduct of the disinfection process.	2	1	2-bromocarboxylic acid; monocarboxylic acid; organochlorine compound
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one [no description available]	2.89	3	benzodiazepine
tenatoprazole Tenatoprazole: structure in first source	2.89	3	imidazopyridine
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	2.43	2	stilbene
s 1033 [no description available]	2.89	3	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
3-(4-pyridyl)-1h-indole 3-(4-pyridyl)-1H-indole: structure in first source	2.08	1	indoles
5-[(2-fluoroanilino)methyl]-8-quinolinol [no description available]	2.89	3	hydroxyquinoline
benidipine hydrochloride [no description available]	2.59	2
benidipine benidipine: RN refers to (R,R)-(+-)-isomer	2.21	1
r 59949 R 59949: diacylglycerol kinase inhibitor	2.72	3	diarylmethane
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one [no description available]	2.89	3	quinazolines
sesquiterpenes [no description available]	2.03	1
chlorprothixene (E)-chlorprothixene : A chlorprothixene in which the double bond adopts an (E)-configuration.	2.89	3	chlorprothixene
etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.	2.06	1	ethyl ester; imidazoles	intravenous anaesthetic; sedative
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	3.25	1	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
3,3',4,5'-tetrahydroxystilbene 3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.	2.71	3	catechols; polyphenol; resorcinols; stilbenol	antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor
3,4-methylenedioxy-beta-nitrostyrene 3,4-methylenedioxy-beta-nitrostyrene: tyrosine kinase inhibitor that prevents platelet glycoprotein IIb/IIIa activation; structure in first source	2.08	1
jrf 12 N2,N4-dibenzylquinazoline-2,4-diamine: a selective, potent, reversible, and ATP-competitive p97 inhibitor	2.89	3
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester [no description available]	2.89	3	methoxybenzenes; substituted aniline
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol [no description available]	2.48	2	substituted aniline
3-hydroxypyridine, sodium salt [no description available]	2.89	3
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide [no description available]	3.07	4	naphthalenecarboxamide
5-[(2-bromoanilino)methyl]-8-quinolinol [no description available]	2.89	3	hydroxyquinoline
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide 3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide: structure in first source	3.06	4
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline [no description available]	2.89	3	aromatic amine
cct018159 CCT018159: structure in first source. CCT-018159 : A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively.	2.06	1	benzodioxine; pyrazoles; resorcinols	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide [no description available]	2.89	3	piperidinecarboxamide
2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide [no description available]	2.08	1	dimethoxybenzene
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol [no description available]	2.89	3	hydroxyquinoline
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide [no description available]	2.89	3	acetamides; anilide
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide [no description available]	2.89	3	aromatic amide; thiophenes
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone [no description available]	2.89	3	dimethoxybenzene
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide [no description available]	2.89	3	aromatic amide
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide [no description available]	2.89	3	aromatic ether
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione [no description available]	2.89	3	maleimides
Src Inhibitor-1 Src Inhibitor-1 : A member of the class of quinazolines that is quinazoline which is substituted at position 4 by a p-phenoxyanilino group and at positions 6 and 7 by methoxy groups. It is a potent, competitive dual site (both the ATP- and peptide-binding) Src kinase inhibitor. Src Inhibitor-1 is one of the 'gold standards' for Src kinase inhibition that has been shown to use PP1 or PP2 in parallel with Src-I1 to inhbit Src family kinases.	3.21	5	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one [no description available]	2.89	3	dimethoxybenzene
cinnarizine Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.	2.03	1	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide [no description available]	2.89	3	quinolines
tg 003 TG 003: a Clk inhibitor; structure in first source	2.46	2
N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline [no description available]	2.08	1	benzimidazoles
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine [no description available]	2.89	3	pyrroles
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.45	2	one-carbon compound; thioureas; ureas	antioxidant; chromophore
tamoxifen [no description available]	2.94	4	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
bi-78d3 [no description available]	2.89	3	aryl sulfide
stattic [no description available]	2.05	1	1-benzothiophenes; C-nitro compound; sulfone	antineoplastic agent; radiosensitizing agent; STAT3 inhibitor
cgp 74514a [no description available]	2.08	1
sc 514 SC 514: inhibits IkappaB kinase-2; structure in first source	2.03	1	ring assembly; thiophenes
kartogenin kartogenin: promotes chondrocyte differentiation; structure in first source	2.89	3
sirtinol [no description available]	2.03	1	aldimine; benzamides; naphthols	anti-inflammatory agent; EC 3.5.1.98 (histone deacetylase) inhibitor; Sir2 inhibitor
1,4-dimethoxy-10H-acridine-9-thione [no description available]	2.08	1	acridines
toremifene Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.	2.48	2	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	4.17	16	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	2.06	1	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
quinine [no description available]	3.25	1	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester [no description available]	3.81	11
rtki cpd RTKI cpd: preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors	2.07	1
sf 2370 SF 2370: indolocarbazole isolated from Actinomadura sp. SF-2370; structure given in first source. K-252a : A organic heterooctacyclic compound that is a potent inhibitor of protein kinase C and is isolated from Nocardiopsis sp K-252a	2.08	1	bridged compound; gamma-lactam; methyl ester; organic heterooctacyclic compound	antimicrobial agent; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; tropomyosin-related kinase B receptor antagonist
sch 23390 SCH 23390: a selective D1-receptor antagonist. SCH 23390 : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 7 and a hydroxy substituent at position 8.	2.51	2	benzazepine
tandutinib [no description available]	2.06	1	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745 [no description available]	3.06	4	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
safingol safingol: RN given refers to the (R-(R,S))-isomer	2.41	2	amino alcohol
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	3.21	5	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
7-epi-hydroxystaurosporine [no description available]	2.03	1
zd 6474 CH 331: structure in first source	3.06	4	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
silybin [no description available]	3.25	1
N-methyl-2-[[3-[2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide [no description available]	2.06	1	aryl sulfide
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide [no description available]	2.83	3	indoles
nih-12848 NIH-12848: inhibits phosphatidylinositol 5-phosphate 4-kinase gamma; structure in first source	2.89	3
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide [no description available]	2.89	3	quinazolines
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone [no description available]	2.89	3	benzimidazoles
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile [no description available]	2.89	3	imidazopyridine
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one [no description available]	2.89	3	aromatic ketone
1,8-dinitro-4,5-dihydroxyanthraquinone 1,8-dinitro-4,5-dihydroxyanthraquinone: structure in first source	3.25	1
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester [no description available]	2.89	3	oxopurine
gtp 14564 [no description available]	2.46	2	pyrazoles; ring assembly
sb 218078 [no description available]	2.46	2	indolocarbazole
sto 609 STO 609: structure in first source	2.08	1	naphthoic acid
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester [no description available]	2.89	3	organonitrogen compound; organosulfur compound
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide [no description available]	2.89	3	quinolines
7-butyl-6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine [no description available]	2.08	1	pyrroles
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2	1	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
LSM-1924 [no description available]	2.89	3	organic heterotricyclic compound; organooxygen compound
ferrostatin-1 ferrostatin-1: inhibits ferroptosis, an iron-dependent form of nonapoptotic cell death; structure in first source. ferrostatin-1 : An ethyl ester resulting from the formal condensation of the carboxy group of 3-amino-4-(cyclohexylamino)benzoic acid with ethanol. It is a potent inhibitor of ferroptosis, a distinct non-apoptotic form of cell death caused by lipid peroxidation. It is also a radical-trapping antioxidant and has the ability to reduce the accumulation of lipid peroxides and chain-carrying peroxyl radicals.	2.89	3	ethyl ester; primary arylamine; substituted aniline	antifungal agent; antioxidant; ferroptosis inhibitor; neuroprotective agent; radiation protective agent; radical scavenger
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor. TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease.	2.08	1	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sb 415286 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source	2.03	1	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
d 609 [no description available]	2.42	2
2',3'-dialdehyde atp 2',3'-dialdehyde ATP: RN given refers to (R-(R,R))-isomer; OATP also stands for organic anion-transporting polypeptides	2.01	1
sc 560 SC560 : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-methoxyphenyl, trifluoromethyl and 4-chlorophenyl groups, respectively. Unlike many members of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors, SC-560 is selective for COX-1.	2.03	1	aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine [no description available]	2.89	3	C-nitro compound
ver-49009 VER-49009: inhibits heat shock protein 90 molecular chaperone; structure in first source. 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)pyrazole-3-carboxamide : An aromatic amide obtained by formal condensation of the carboxy group of 5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)pyrazole-3-carboxylic acid with the amino group of ethylamine.	2.06	1	aromatic amide; monochlorobenzenes; monomethoxybenzene; pyrazoles; resorcinols	Hsp90 inhibitor
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	2.06	1	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
rabeprazole(1-) [no description available]	2.63	2	organic nitrogen anion
myelin basic protein Myelin Basic Protein: An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.	2	1
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.97	4	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
imd 0354 N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source	2.06	1	benzamides
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-ylemine [no description available]	2.46	2	pyrazolopyrimidine	tyrosine kinase inhibitor
ncgc00099374 [no description available]	2.89	3
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide [no description available]	2.89	3	benzamides
ku 55933 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source	2.78	3
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	3.51	8	sphing-4-enine	human metabolite; mouse metabolite
quercetin [no description available]	2.71	3	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.76	3	prostaglandins E	human metabolite; mouse metabolite; oxytocic
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	2	1	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
arachidonyltrifluoromethane arachidonyltrifluoromethane: structure given in first source; inhibits 85-kDa phospholipase A2. AACOCF3 : A fatty acid derivative that is arachidonic acid in which the OH part of the carboxy group has been replaced by a trifluoromethyl group	2.4	2	fatty acid derivative; ketone; olefinic compound; organofluorine compound	EC 3.1.1.4 (phospholipase A2) inhibitor
acacetin 5,7-dihydroxy-4'-methoxyflavone : A monomethoxyflavone that is the 4'-methyl ether derivative of apigenin.	2.06	1	dihydroxyflavone; monomethoxyflavone	anticonvulsant; plant metabolite
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	3.85	3	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	4.2	4	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2	1	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	2.42	2	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	2.42	2	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
thromboxane a2 Thromboxane A2: An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).. thromboxane A2 : A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.	2.42	2	epoxy monocarboxylic acid; thromboxanes A	mouse metabolite
daphnetin [no description available]	2.03	1	hydroxycoumarin
cyclosporine [no description available]	2.21	1
kaempferol [no description available]	2.89	3	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
leukotriene d4 Leukotriene D4: One of the biologically active principles of SRS-A. It is generated from LEUKOTRIENE C4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene D4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R).	2.08	1	dipeptide; leukotriene; organic sulfide	bronchoconstrictor agent; human metabolite; mouse metabolite
harmine Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.	2.03	1	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
genistein [no description available]	4.16	16	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	2.89	3	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
bruceantin [no description available]	2.89	3	triterpenoid
harman harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.	2.03	1	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	4.2	4	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
fisetin [no description available]	3.25	1	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
euxanthone euxanthone : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1 and 7 and an oxo group at position 9. It has been isolated from Cratoxylum cochinchinense.	2.42	2	phenols; xanthones	metabolite; plant metabolite
quercetagetin quercetagetin: structure given in first source; inhibits aldose reductase in rat lens. quercetagetin : A hexahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 5, 6, 7, 3' and 4' respectively.	3.25	1	flavonols; hexahydroxyflavone	antioxidant; antiviral agent; plant metabolite
daidzein [no description available]	2.89	3	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
caffeic acid phenethyl ester phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.	2.05	1	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
wedelolactone wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source. wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3.	2.03	1	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite
rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.	5.47	62	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
neticonazole neticonazole: RN refers to (E)-isomer. neticonazole : An enamine that is ethene which is substituted at positions 1, 1, and 2 by o-pentoxyphenyl, 1H-imidazol-1-yl, and methylthio groups, respectively (the E isomer). An inhibitor of P450-dependent C-14alpha-demethylation of lanosterol (preventing conversion to ergosterol and inhibiting cell wall synthesis in fungi), it is used in Japan (generally as the corresponding hydrochloride salt) as an antifungal drug for the treatment of superficial skin infections.	2.89	3	aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide	antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
20-hydroxy-5,8,11,14-eicosatetraenoic acid 20-hydroxy-5,8,11,14-eicosatetraenoic acid: stimulator of renal sodium, potassium atpase; RN given is for the (all-Z) isomer. 20-HETE : A HETE that consists of arachidonic acid bearing a hydroxy substituent at position 20.	2.08	1	HETE; hydroxy monocarboxylic acid	human metabolite; mouse metabolite
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine synaptamide: structurally similar to the endocannabinoid N-arachidonoylethanolamine (anandamide). N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine : An N-acylethanolamine 22:6 that is the ethanolamide of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid.	2.89	3	endocannabinoid; N-acylethanolamine 22:6
n-oleoylethanolamine N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.	2.89	3	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
sphingosine 1-phosphate sphingosine 1-phosphate: RN given refers to (R-(R,S-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1	2.7	3	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	3.42	7	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
alpha-zearalenol [no description available]	2.89	3	macrolide
brefeldin a [no description available]	3.11	5	macrolide antibiotic	Penicillium metabolite
as 604850 [no description available]	2.08	1
fenretinide Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.	3.25	1	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant
geldanamycin [no description available]	2.44	2	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.11	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
su 9516 [no description available]	3.21	5
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine [no description available]	2.89	3	triazolopyrimidines
dexmedetomidine [no description available]	2.11	1	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
sb 277011 SB 277011: structure in first source	2.89	3
herbimycin herbimycin: herbicidal antibiotic produced by Streptomyces sp.; see also herbimycin B; structure for herbimycin A in second source. herbimycin : A 19-membered macrocyle incorporating a benzoquinone ring and a lactam functionality. It is an ansamycin antibiotic that induces apoptosis and displays antitumour effects.	2.93	4	1,4-benzoquinones; lactam; macrocycle	antimicrobial agent; apoptosis inducer; herbicide; Hsp90 inhibitor; tyrosine kinase inhibitor
lysophosphatidic acid lysophosphatidic acid: RN given refers to parent cpd. 1-oleoyl-sn-glycerol 3-phosphate : A 1-acyl-sn-glycerol 3-phosphate having oleoyl as the 1-O-acyl group.. lysophosphatidic acid : A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class.	2.72	3	1-acyl-sn-glycerol 3-phosphate
pd 166285 [no description available]	2.06	1
sb 223412 SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source	2.89	3
sr 59230a [no description available]	2.89	3	tetralins
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide [no description available]	3.07	4	pyrimidines
kn 93 KN 93: reduces dopamine content in PC12h cells. KN-93 : A sulfonamide resulting from the formal condensation of p-methoxybenzenesulfonic acid with the anilino nitrogen of 2-(aminomethyl)-N-(2-hydroxyethyl)aniline in which the hydrogens of the primary amino group have been replaced by methyl and p-chlorocinnamyl groups. KN-93 is a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II.	3.14	5	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector
kn 62 KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II	3.33	6	piperazines
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.74	3
MeJA [no description available]	2.89	3	Jasmonate derivatives
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)- 1H-pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-: structure in first source	2.89	3
pd 161570 PD 161570: structure in first source	2.89	3
tyrphostin ag-494 AG 494: tyrphostin that blocks Cdk2 activation; structure in first source	2.03	1
ag-490 [no description available]	3.15	5	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
ag 127 AG 127: structure given in first source	1.99	1
ag 112 [no description available]	2.08	1
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	2.08	1	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
orantinib orantinib: an antiangiogenic agent. orantinib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.	2.03	1
su 11248 [no description available]	2.75	3	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
su 11652 SU 11652: a tyrosine kinase inhibitor; amino acid sequence in first source. SU11652 : A member of the class of pyrrolecarboxamides obtained by formal condensation of the carboxy group of 5-[(Z)-(5-chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethylpyrrole-3-carboxylic acid with the primary amino group of N(1),N(1)-diethylethane-1,2-diamine.	2.46	2	olefinic compound; organochlorine compound; oxindoles; pyrrolecarboxamide; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor
6-(4-methoxyphenyl)-3-(3-thiophenyl)pyrazolo[1,5-a]pyrimidine [no description available]	2.08	1	pyrimidines
palbociclib [no description available]	3.06	4	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621 [no description available]	3.23	5	sulfonamide
12-hydroxy-5,8,10,14-eicosatetraenoic acid 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51)	2.01	1
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.95	4	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
brevetoxin t17 brevetoxin T17: from Florida red tide organism Ptychodiscus brevis; neuromuscular blocking action; structure given in first source	2	1
methyl 2,5-dihydroxycinnamate methyl 2,5-dihydroxycinnamate: structure given in first source. 2,5-dihydroxycinnamic acid methyl ester : A cinnamate ester that is the methyl ester of 2,5-dihydroxycinnamic acid.	2.03	1	cinnamate ester; hydroquinones; methyl ester	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; geroprotector; human urinary metabolite; plant metabolite
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.	2.03	1	dihydroxy monocarboxylic acid; indoles; organofluorine compound
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid: A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)	2	1
barium Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous.	2.95	4	alkaline earth metal atom; elemental barium
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	2.45	2	metalloid atom; pnictogen	micronutrient
virginiamycin factor s1 virginiamycin factor S1: a component of VIRGINIAMYCIN; was EP to VIRGINIAMYCIN 1992-2001. virginiamycin S1 : A cyclodepsipeptide that is N-(3-hydroxypicolinoyl)-L-threonyl-D-alpha-aminobutyryl-L-prolyl-N-methyl-L-phenylalanyl-4-oxo-L-pipecoloyl-L-2-phenylglycine in which the carboxy group of the 2-phenylglycine moiety has undergone formal intramolecular condensation with the hydroxy group of the N-(3-hydroxypicolinoyl)-L-threonyl to give the corresponding 19-membered ring lactone. It is one of the two major components of the antibacterial drug virginiamycin, produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others.	2.89	3	cyclodepsipeptide; macrolide antibiotic	antibacterial drug; bacterial metabolite
cytochalasin e cytochalasin E: structure	2.01	1	cytochalasan alkaloid	metabolite
ophiocordin ophiocordin: metabolite of Cordyceps ophioglossoides	3.1	1
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one: a janus-activated kinase inhibitor. 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one : An organic heterotetracyclic compound that is 1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one bearing additional tert-butyl and fluoro substituents at positions 2 and 9 respectively.	2.75	3	organic heterotetracyclic compound; organofluorine compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
vx680 [no description available]	2.97	4	N-arylpiperazine
fenoterol fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.	2.63	2	hydrobromide	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
xib 4035 XIB 4035: a GFRalpha-1 agonist; structure in first source	2.89	3
gw-5074 [no description available]	2.78	3
st 638 [no description available]	2.03	1
su 1498 SU 1498: structure in first source. SU1498 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2E)-2-cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]prop-2-enoic acid with the amino group of 3-phenylpropylamine.	2.03	1	enamide; monocarboxylic acid amide; nitrile; phenols; secondary carboxamide	vascular endothelial growth factor receptor antagonist
12-o-retinoylphorbol-13-acetate [no description available]	2.72	3
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	2.03	1	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
tetrodotoxin Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.	2.43	2	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker
oxalates Oxalates: Derivatives of OXALIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are derived from the ethanedioic acid structure.	2.03	1
ml 3403 [no description available]	2.46	2
d 4476 [no description available]	2.74	3	imidazoles
GSK3-XIII GSK3-XIII : A member of the class of aromatic amines that is ammonia with two of the hydrogens replaced by 5-methylpyrazol-3-yl and 2-phenylquinazolin-4-yl groups.	2.46	2	aromatic amine; pyrazoles; quinazolines; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
antimycin a Antimycin A: An antibiotic substance produced by Streptomyces species. It inhibits mitochondrial respiration and may deplete cellular levels of ATP. Antimycin A1 has been used as a fungicide, insecticide, and miticide. (From Merck Index, 12th ed). antimycin A : A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison.	2.17	1	amidobenzoic acid
cyc 116 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: an aurora kinase inhibitor; structure in first source	2.06	1
herbimycin [no description available]	2.08	1
1-oleoyl-2-acetylglycerol [no description available]	2.41	2	1,2-diglyceride
involucrin involucrin: soluble precursor protein of cross-linked envelope characteristic of epidermal s. corneum synthesized by keratinocytes in natural & cultured human epithelia; see also related records for prekeratin & stratum corneum basic protein precursor	2.41	2
concanamycin a concanamycin A: from Streptomyces diastatochromogenes S-45; inhibits vacuolar H+ ATPase. concanamycin A : A concanamycin in which the lactone ring contains 4 double bonds and is substituted by 4 methyl groups, 2 hydroxy groups, 2 methoxy groups and an ethyl group.	2.07	1	carbamate ester; concanamycin	antifungal agent; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; metabolite
manumycin manumycin: an NSAID; RN given for (1S-(1alpha,3(2E,4E,6S*),5alpha,5(1E,3E,5E),6alpha))-isomer; a farnesyl protein transferase inhibitor; from Streptomyces parvulus; MF C31-H38-N2-O7; structure given in first source. manumycin A : A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties.	2.04	1	enamide; epoxide; organic heterobicyclic compound; polyketide; secondary carboxamide; tertiary alcohol	antiatherosclerotic agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; marine metabolite
igmesine [no description available]	2.01	1
axitinib [no description available]	2.46	2	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
su 4312 SU4312 : A member of the class of oxindoles that is 3-methyleneoxindole in which one of the hydrogens of the methylene group has been replaced by a p-(dimethylamino)phenyl group. SU 4312 is a vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 and platelet derived growth factor (PDGF) receptor inhibitor. It also inhibits the neuronal nitric oxide synthase (NOS) and exhibits neuroprotection against NO-mediated neurotoxicity.	2.08	1
belotecan belotecan: structure in first source	2.89	3	pyranoindolizinoquinoline
tanespimycin CP 127374: analog of herbimycin A	2.46	2	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
fm1 43 FM1 43: labels motor nerve terminals in an activity-dependent fashion that involves dye uptake by synaptic vesicles that are recycling; structure given in second source	2	1	organic bromide salt; pyridinium salt; quaternary ammonium salt; tertiary amine	fluorochrome
gw 1929 GW 1929: activates peroxisome proliferator-activated receptor-gamma; structure in first source	2.03	1	benzophenones
1-azakenpaullone 1-azakenpaullone : An organic heterotetracyclic compound that is 7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indole substituted at positions 6 and 9 by oxo and bromo groups respectively.	2.06	1	lactam; organic heterotetracyclic compound; organobromine compound; organonitrogen heterocyclic compound	EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole [no description available]	2.74	3	aryl sulfide
a 419259 [no description available]	2.06	1
gdp 366 GDP 366: an antineoplastic agent; structure in first source	2.45	2
norgestimate [no description available]	2.89	3	ketoxime; steroid ester; terminal acetylenic compound	contraceptive drug; progestin; synthetic oral contraceptive
b 43 RK-24466 : A member of the class of pyrrolopyrimidines that is 7H-pyrrolo[2,3-d]pyrimidine substituted by amino, 4-phenoxyphenyl, and cyclopentyl groups at positions 4, 5 and 7, respectively. It is a potent inhibitor of Lck that inhibits Lck (64-509) and LckCD isoforms (IC50 of less than 1 and 2 nM, respectively).	3.07	4	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine [no description available]	2.89	3
methiazole methiazole: a parasitostatic agent	2.89	3	benzimidazoles; carbamate ester
sb 218795 SB 218795: structure in first source	2.89	3	quinolines
sb 334867-a 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea: selective OX1 receptor antagonist	2.17	1	naphthyridine derivative
aminopurvalanol a aminopurvalanol A: casein kinase I alpha inhibitor; structure in first source	2.46	2	monochlorobenzenes; purvalanol	protein kinase inhibitor
bvt.948 [no description available]	2.89	3
cgk 733 [no description available]	2.08	1	diarylmethane
2-[[6-[(phenylmethyl)amino]-9-propan-2-yl-2-purinyl]amino]ethanol [no description available]	2.06	1	thiopurine
cgp 53353 4,5-bis(4-fluoroanilino)phthalimide: structure in first source	2.08	1	phthalimides
adenosine-3',5'-cyclic phosphorothioate adenosine-3',5'-cyclic phosphorothioate: RP-cAMP-S is a protein kinase A inhibitor; SP-cAMP-S is a protein kinase A agonist. (Sp)-cAMPS : A nucleoside 3',5'-cyclic phosphorothioate having adenine as the nucleobase (the Sp-stereoisomer).. (Rp)-cAMPS : A nucleoside 3',5'-cyclic phosphorothioate having adenine as the nucleobase (the Rp-stereoisomer).	2.11	1	nucleoside 3',5'-cyclic phosphorothioate
sq-23377 Ionomycin: A divalent calcium ionophore that is widely used as a tool to investigate the role of intracellular calcium in cellular processes.. ionomycin : A very long-chain fatty acid that is docosa-10,16-dienoic acid which is substituted by methyl groups at positions 4, 6, 8, 12, 14, 18 and 20, by hydroxy groups at positions 11, 19 and 21, and by a (2',5-dimethyloctahydro-2,2'-bifuran-5-yl)ethanol group at position 21. An ionophore produced by Streptomyces conglobatus, it is used in research to raise the intracellular level of Ca(2+) and as a research tool to understand Ca(2+) transport across biological membranes.	3.72	10	cyclic ether; enol; polyunsaturated fatty acid; very long-chain fatty acid	calcium ionophore; metabolite
fk 866 N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source	2.21	1	benzamides; N-acylpiperidine
enkephalin, leucine-2-alanine Enkephalin, Leucine-2-Alanine: A delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.	2.01	1
a 38503 [no description available]	2.89	3
ci 940 leptomycin : A complex, very long chain, polyunsaturated fatty acid whose core structure comprises 8-oxononadeca-2,10,12,16,18-pentaenoic acid having methyl substituents at positions 3, 5, 7, 9, 11 and 15 and a 3,6-dihydropyran-6-one-2-yl group at position 19.	2.03	1	hydroxy polyunsaturated fatty acid; leptomycin	antifungal agent; bacterial metabolite
cvt 313 CVT 313: a potent inhibitor of CDK2 that prevents neointimal proliferation; structure given in first source	2.46	2
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.42	2	aminobenzoic acid
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	2.03	1	substituted aniline
staurosporine staurosporinium : Conjugate acid of staurosporine.	4.88	34	ammonium ion derivative
parthenolide [no description available]	2.58	2	sesquiterpene lactone	drug allergen; inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
a 770041 [no description available]	2.06	1	aromatic amide
sl 327 SL 327: a MEK inhibitor. SL-327 : A nitrile that is acrylonitrile in which the hydrogen attached to the same carbon as the cyano group has been replaced by an o-(trifluoromethyl)phenyl group, while the remaining hydrogens of the ethenyl group have been replaced by amino and (4-aminophenyl)sulfanyl groups. The configuration of the double bond is not specified. It is an inhibitor of MEK1 and MEK2.	2.03	1
tws 119 [no description available]	2.46	2	pyrroles
krn 633 N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea: a VEGF receptor-2 tyrosine kinase inhibitor; structure in first source	3.04	4
((3z)-n-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1h-pyrrol-2-yl)methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide) [no description available]	2.03	1	sulfonamide
c 1368 [no description available]	2.46	2
pq 401 PQ 401: an IGF receptor type I antagonist; structure in first source	2.46	2	quinolines
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid [no description available]	2.89	3	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
jnj 10198409 [no description available]	2.46	2
gw 501516 GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.	2.89	3	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist
dolastatin 10 dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization.	2.89	3	1,3-thiazoles; tetrapeptide	animal metabolite; antineoplastic agent; apoptosis inducer; marine metabolite; microtubule-destabilising agent
cp 547632 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source	2.45	2
bms345541 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline: structure in first source	2.45	2	quinoxaline derivative
spc-839 SPC-839: an inhibitor of activator protein 1; structure in first source	2.89	3
kb r7943 2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate: inhibits the reverse mode of Na+/Ca++ exchange in cells expressing NCX1; structure in first source	2.05	1
adw 742 [no description available]	2.06	1
gw843682x [no description available]	2.45	2	(trifluoromethyl)benzenes
pd 0325901 mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).	2.03	1	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	3.45	7	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
muromonab-cd3 xestospongin C: was indexed to xestospongin A; from Xestospongia sponge; empties the ER calcium store but does not inhibit InsP3-induced Ca2+ release. xestospongin C : An organic heteropentacyclic compound that is isolated from the marine sponge Xestospongia exigua.	2.21	1	alkaloid; macrocycle; organic heteropentacyclic compound; organonitrogen heterocyclic compound; oxacycle; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; IP3 receptor antagonist; marine metabolite
ursodoxicoltaurine tauroursodeoxycholate : An organosulfonate oxoanion that is the conjugate base of tauroursodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. tauroursodeoxycholic acid : A bile acid taurine conjugate derived from ursoodeoxycholic acid.	2.04	1	bile acid taurine conjugate	anti-inflammatory agent; apoptosis inhibitor; bone density conservation agent; cardioprotective agent; human metabolite; neuroprotective agent
valnemulin [no description available]	2.63	2
sb-505124 SB 505124 : A member of the class of imidazoles carrying tert-butyl, 1,3-benzodioxol-5-yl and 6-methylpyridin-2-yl substituents at positions 2, 4 and 5 respectively.	2.08	1	benzodioxole; imidazoles; methylpyridines	TGFbeta receptor antagonist
ic 86621 1-(2-hydroxy-4-morpholin-4-ylphenyl)ethanone: a DNA-dependent protein kinase inhibitor	2.08	1	aromatic ketone
nu 7026 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source	3.21	5	organic heterotricyclic compound; organooxygen compound
sb 242235 SB 242235: p38 MAP kinase antagonist	2.06	1
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.06	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
osi 930 OSI 930: inhibits both receptor tyrosine kinase Kit and kinase insert domain receptor; structure in first source	2.89	3	aromatic amide
ticagrelor Ticagrelor: An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.. ticagrelor : A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome.	2.89	3	aryl sulfide; hydroxyether; organofluorine compound; secondary amino compound; triazolopyrimidines	P2Y12 receptor antagonist; platelet aggregation inhibitor
l 692585 [no description available]	2.89	3	peptide
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	3.47	7	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
nnc 26-9100 NNC 26-9100: structure in first source	2.89	3	aminopyridine
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine [no description available]	2.89	3
y 27632, dihydrochloride, (4(r)-trans)-isomer [no description available]	2.03	1
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide: an IKK-2 kinase inhibitor; structure in first source	2.08	1	aromatic amide; thiophenes
tgx 221 TGX 221: a platelet aggregation inhibitor	2.06	1	pyridopyrimidine
tivozanib N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source	3.07	4	aromatic ether
zm 447439 ZM447439 : A member of the class of quinazolines that is quinazoline which is substituted at positions 4, 6 and 7 by a (4-benzamidophenyl)nitrilo group, methoxy group and a 3-(morpholin-4-yl)propoxy group, respectively. It is an ATP-competitive inhibitor of Aurora A and Aurora B kinases with IC50 of 110 nM and 130 nM, respectively.	2.06	1	aromatic ether; benzamides; morpholines; polyether; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; Aurora kinase inhibitor
hki 272 [no description available]	2.21	1	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide [no description available]	2.89	3
pifithrin-alpha [no description available]	2.03	1
rucaparib AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source	2.06	1	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cediranib [no description available]	2.06	1	aromatic ether
tae226 TAE226: an adhesion kinase inhibitor, offers an attractive therapeutic approach in ovarian carcinoma; structure in first source	3.06	4	morpholines
gw0742 GW 610742: structure in first source	2.89	3	monocarboxylic acid
ps1145 PS1145: IkappaB kinase inhibitor; structure in first source	2.03	1	beta-carbolines
tak-715 N-(4-(2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl)-2-pyridyl)benzamide: anti-rheumatoid arthritis agent; structure in first source	2.06	1	benzamides
u 18666a 3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one: inhibits cycloartenol synthase. 3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride : A hydrochloride obtained by reaction of 3beta-(2-diethylaminoethoxy)androst-5-en-17-one with one equivalent of hydrochloric acid. It is a cholesterol synthesis and transport inhibitor.	2.89	3	hydrochloride	antiviral agent; EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor; Hedgehog signaling pathway inhibitor; nicotinic antagonist; sterol biosynthesis inhibitor
chir 99021 Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.	2.45	2	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
sb 525334 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline: a TGF-betaR kinase inhibitor	2.89	3	quinoxaline derivative
cgp 20712a CGP 20712A: structure given in first source; CGP 26505, a beta1-selective beta-adrenoceptor antagonist, is the (S)-isomer of CGP 20712A	2.03	1
ly2090314 LY-2090314 : A member of the class of diazepinoindoles that is 1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indole substituted by piperidin-1-ylcarbonyl, 4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl and fluoro groups at position 2, 7 and 9, respectively. It is a potent ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3alpha and GSK-3beta. The drug is in clinical development for the treatment of advanced/metastatic cancer.	2.06	1	diazepinoindole; imidazopyridine; maleimides; monofluorobenzenes; piperidinecarboxamide; ureas	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator
bx795 BX795: structure in first source	3.04	4	ureas
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	2.06	1	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
azd 6244 AZD 6244: a MEK inhibitor	2.89	3	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea: structure in first source	2.89	3
a 443654 A 443654: an Akt kinase inhibitor; structure in first source	2.03	1	indoles
bay 61-3606 [no description available]	3.06	4	pyrimidines
nu 6140 4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide: a cyclin-dependent kinase inhibitor; structure in first source	2.08	1
sotrastaurin sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source. sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients.	3.9	3	indoles; maleimides; N-alkylpiperazine; N-arylpiperazine; quinazolines	anticoronaviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunosuppressive agent
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	2.1	1
sd-208 [no description available]	2.89	3
vx 702 VX 702: a p38 MAP kinase inhibitor	2.06	1	phenylpyridine
crenolanib [no description available]	2.89	3	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cj 033466 CJ 033466: structure in first source	2.89	3
cc 401 CC 401: an anthrapyrazolone	2.89	3	pyrazoles; ring assembly
sl0101 SL0101: p90 Ribosomal S6 Kinase; structure in first source	2.03	1
PB28 PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.	2.89	3	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
arterolane arterolane: a trioxolane with antimalarial activity; structure in first source. arterolane : An oxaspiro compound that is dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.1(3,7)]decane] substituted by a 2-[(2-amino-2-methylpropyl)amino]-2-oxoethyl group at position 4s. Its maleic acid salt is used as an antimalarial drug in combination with piperaquine.	2.89	3
PDGF receptor tyrosine kinase inhibitor III PDGF receptor tyrosine kinase inhibitor III : An N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a (4-phenoxyphenyl)aminocarbonyl group, while the hydrogen attached to the nitrogen at position 4 is replaced by a 6,7-dimethoxyquinazolin-4-yl group. It is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT.	2.08	1	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; quinazolines; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ucn 1028 c calphostin C: structure given in first source; isolated from Cladosporium cladosporioides	4.88	34
cariprazine cariprazine: Structure in first source. cariprazine : An N-alkylpiperazine that is N,N-dimethyl-N'-{trans-4-[2-(piperazin-1-yl)ethyl]cyclohexyl}urea substituted at position 4 on the piperazine ring by a 2,3-dichlorophenyl group. Used (as the hydrochloride salt) for treatment of schizophrenia and bipolar disorder.	2.89	3
krp-203 [no description available]	2.89	3
regorafenib [no description available]	2.89	3	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
at 7867 [no description available]	2.89	3	monochlorobenzenes; piperidines; pyrazoles	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester [no description available]	2.89	3	pyrroloquinoline
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one [no description available]	2.06	1	methoxybenzenes; substituted aniline
ptc 124 [no description available]	2.89	3	oxadiazole; ring assembly
degrasyn degrasyn: a JAK2 kinase inhibitor that induces rapid degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines; structure in first source	2.63	2
cvt-6883 3-ethyl-1-propyl-8-(1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione: structure in first source	2.06	1
bi 2536 [no description available]	3.04	4
4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide [no description available]	2.08	1	biphenyls
r 1487 [no description available]	2.06	1
nvp-ast487 NVP-AST487: antineoplastic; a RET kinase inhibitor that blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells	2.06	1
abt 869 [no description available]	2.06	1	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
fr 180204 FR 180204: structure in first source	2.46	2	pyrazoles; ring assembly
azd 1152 AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.	3.06	4	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug
dorsomorphin dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.	2.46	2	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
ro 31-8425 Ro 31-8425: structure given in first source	2.11	1
ki11502 Ki11502: a multitargeted receptor tyrosine kinase inhibitor that induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo; structure in first source. Ki11502 : A member of the class of quinolines that acts as a receptor tyrosine kinase inhibitor and apoptosis inducer with potential for use in treatment of leukemia and colorectal cancer.	2.08	1	aromatic ether; benzamides; quinolines; thioureas	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
carfilzomib [no description available]	2.89	3	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine : A pyrazolylpiperidine that consists of 4-(pyrazol-1-yl)piperidine carrying a 2-amino-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-5-yl group at the 4-position of the pyrazole ring.. rac-crizotinib : A racemate comprising equimolar amounts of (R)- and (S)-crizotinib. The active (R)-enantiomer acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.	2.06	1	aminopyridine; aromatic ether; dichlorobenzene; organofluorine compound; pyrazolylpiperidine; racemate	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
veratridine Veratridine: A benzoate-cevane found in VERATRUM and Schoenocaulon. It activates SODIUM CHANNELS to stay open longer than normal.	2.43	2
gw 2580 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source	2.75	3
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	2.89	3	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
osi 906 [no description available]	2.06	1	cyclobutanes; quinolines
cgp 57380 CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1	2.46	2	pyrazolopyrimidine
motesanib [no description available]	2.89	3	pyridinecarboxamide
mln8054 [no description available]	2.06	1	benzazepine
pf-562,271 [no description available]	3.06	4	indoles
pha 767491 PHA 767491: a Cdc7 inhibitor; structure in first source	2.06	1	pyrrolopyridine
gpi 15427 [no description available]	2.06	1
gliocladin c gliocladin C: structure in first source	2.89	3
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	2.44	2
sb 706504 [no description available]	2.89	3
calcimycin Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.	3.11	5	benzoxazole
ku-0060648 [no description available]	2.89	3	dibenzothiophenes
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.06	1	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
bgt226 BGT226 free base : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor.. BGT226 : The maleate salt of 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one. A dual PI3K/mTOR inhibitor.	2.89	3	aromatic ether; imidazoquinoline; N-arylpiperazine; organofluorine compound; pyridines	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
n-desmethyldanofloxacin N-desmethyldanofloxacin: structure given in first source	2.89	3
rabeprazole sodium [no description available]	2.15	1	organic sodium salt
a-484954 A-484954: eEF2K inhibitor; structure in first source	2.06	1
azd 1152-hqpa AZD2811: has antineoplastic activity; structure in first source	2.83	3	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor
CDN1163 CDN1163: a SERCA2 activator with antidiabetic activity; structure in first source. CDN1163 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-isopropoxybenzoic acid with the primary amino group of 2-methylquinolin-8-amine. An allosteric activator of sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA).	2.89	3	aromatic ether; quinolines; secondary carboxamide	SERCA activator
nvp-tae684 [no description available]	2.06	1	piperidines
gsk 269962a [no description available]	3.06	4
cholecystokinin Cholecystokinin: A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.	2.06	1
motilin Motilin: A peptide of about 22-amino acids isolated from the DUODENUM. At low pH it inhibits gastric motor activity, whereas at high pH it has a stimulating effect.	2.21	1
atrial natriuretic factor Atrial Natriuretic Factor: A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS.	2.02	1	polypeptide
gastrins Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.	2.44	2
neuropeptide y Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.	1.99	1
angiotensinogen Angiotensinogen: An alpha-globulin of about 453 amino acids, depending on the species. It is produced by the liver in response to lowered blood pressure and secreted into blood circulation. Angiotensinogen is the inactive precursor of the ANGIOTENSINS produced in the body by successive enzyme cleavages. Cleavage of angiotensinogen by RENIN yields the decapeptide ANGIOTENSIN I. Further cleavage of angiotensin I (by ANGIOTENSIN CONVERTING ENZYME) yields the potent vasoconstrictor octapeptide ANGIOTENSIN II; and then, via other enzymes, other angiotensins also involved in the hemodynamic-regulating RENIN-ANGIOTENSIN SYSTEM.	2.08	1
astressin astressin : A 30-membered homodetic cyclic peptide comprising the sequence D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 cyclised by an amide bridge, formed by condensation of the side-chain carboxy group of the Glu residue at position 19 and the side-chain amino group of the Lys residue at position 22.	2.07	1	homodetic cyclic peptide; polypeptide	corticotropin-releasing factor receptor antagonist; neuroprotective agent
c-peptide C-Peptide: The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.	2.03	1
natriuretic peptide, c-type Natriuretic Peptide, C-Type: A PEPTIDE of 22 amino acids, derived mainly from cells of VASCULAR ENDOTHELIUM. It is also found in the BRAIN, major endocrine glands, and other tissues. It shares structural homology with ATRIAL NATRIURETIC FACTOR. It has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. Several high molecular weight forms containing the 22 amino acids have been identified.	2.06	1
cct129202 [no description available]	2.08	1
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	3.27	6
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one [no description available]	2.06	1	indoles
kn 92 KN 92: KN 93 isomer; a calcium/calmodulin-dependent kinase II inhibitor;	2.03	1
pha 848125 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide: a cyclin dependent kinase inhibitor	2.89	3
tg101209 [no description available]	2.06	1	N-alkylpiperazine; N-arylpiperazine; pyrimidines; secondary amino compound; sulfonamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
nvp-bhg712 [no description available]	2.89	3	benzamides
(e)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid: casein kinase II inhibitor	2.08	1
pf 04217903 [no description available]	3.06	4	quinolines
3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile [no description available]	2.06	1	pyrrolopyrimidine
gdc 0941 pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.	2.06	1	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
calpain Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.	2	1
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one [no description available]	2.89	3	aromatic ketone
ph 797804 PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.	3.06	4	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
bucladesine Bucladesine: A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed). bucladesine : A 3',5'-cyclic purine nucleotide that is the 2'-butanoate ester and 6-N-butanoyl derivative of 3',5'-cyclic AMP.	2.7	3	3',5'-cyclic purine nucleotide
srt1720 [no description available]	2.89	3
purfalcamine purfalcamine: a PfCDPK-1 inhibitor; structure in first source	2.89	3
mln 8237 MLN 8237: an aurora kinase A inhibitor	2.06	1	benzazepine
bms 754807 BMS 754807: an IGR-1R kinase inhibitor; structure in first source	2.89	3	pyrazoles; pyridines; pyrrolidines; pyrrolotriazine	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ponatinib [no description available]	2.89	3	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor
mk-1775 adavosertib: a Wee1 kinase inhibitor; structure in first source	2.06	1	piperazines
quizartinib [no description available]	2.89	3	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor
PP121 [no description available]	3.06	4	aromatic amine; cyclopentanes; pyrazolopyrimidine; pyrrolopyridine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; tyrosine kinase inhibitor
navitoclax [no description available]	2.89	3	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
sns 314 SNS 314: an aurora kinase inhibitor; structure in first source	2.06	1	ureas
gsk 650394 [no description available]	2.89	3	phenylpyridine
bi d1870 [no description available]	2.03	1
dcc-2036 rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent	2.89	3	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor
protein kinase c [no description available]	2.01	1
cabozantinib cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.	2.89	3	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
entrectinib entrectinib: inhibits TRK, ROS1, and ALK receptor tyrosine kinases; structure in first source. entrectinib : A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours.	2.06	1	benzamides; difluorobenzene; indazoles; N-methylpiperazine; oxanes; secondary amino compound; secondary carboxamide	antibacterial agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
TAK-580 MLN 2480: brain-penetrant RAF dimer antagonist. TAK-580 : A 1,3-thiazolecarboxamide that is 2-[(1R)-1-aminoethyl]-1,3-thiazole-5-carboxylic acid in which the carboxy group undergoes formal condensation with the amino group of 5-chloro-4-(trifluoromethyl)pyridin-2-amine and in which the amino group undergoes formal condensation with the carboxy group of 6-amino-5-chloropyrimidine-4-carboxylic acid. It is a pan-RAF kinase inhibitor which is currently in clinical development for the treatment of radiographically recurrent or progressive low-grade glioma in children and young adults.	2.89	3	1,3-thiazolecarboxamide; aminopyrimidine; chloropyridine; organofluorine compound; pyrimidinecarboxamide; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one [no description available]	2.89	3	chromones
pf 3758309 PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first source	2.89	3	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol: a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity; structure in first source	2.63	2	benzyl alcohols; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; apoptosis inducer; mTOR inhibitor
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	2.89	3	aryl sulfide; thienopyrimidine
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	2.89	3	aryl sulfide; thienopyrimidine
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	2.89	3	aryl sulfide; thienopyrimidine
glycolipids [no description available]	2	1
baricitinib [no description available]	2.89	3	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.89	3	quinazolines
piperidines Piperidines: A family of hexahydropyridines.	2.7	3
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone ML-265: a small molecule activator of PKM2	2.89	3	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
bryostatin 1 bryostatin 1: a protein kinase C activator; macrocyclic lactone from marine Bryozoan Bugula neritina; RN given refers to (1S-(1R,3R,5Z,7S,8E,11R,12R(2E,4E),13E,15R,17S(S),21S,23S,25R))-isomer; structure given in first source; activates protein kinase c. bryostatin 1 : A member of the class of bryostatins that is (17E)-2-oxooxacyclohexacos-17-ene which is substituted by hydroxy groups at positions 4, 10, and 20; an acetoxy group at position 8; methyl groups at positions 9, 9, 18, and 19; 2-methoxy-2-oxoethylidene groups at positions 14 and 24; an (E,E)-octa-2,4-dienoyloxy group at position 21; and with oxygen bridges linking positions 6 to 10, 12 to 16, and 20 to 24. It is one of the most abundant member of the class of bryostatins.	4.98	12
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	3.87	4
ingenol dibenzoate ingenol dibenzoate: antileukemic component of Euphorbia esula L. extract; structure	2	1
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide [no description available]	2.89	3	hydroxyquinoline
p505-15 [no description available]	2.89	3
mrt67307 MRT67307: IKK (IκB(inhibitor of NF-κB (nuclear factor κB)) kinase) family inhibitor; structure in first source	2.89	3	aromatic amine
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide [no description available]	2.89	3	piperazines
thiopental sodium [no description available]	2.08	1	organochlorine compound; piperazines; pyrimidines	antineoplastic agent; tyrosine kinase inhibitor
ribociclib ribociclib: inhibits both CDK4 and CDK6	2.89	3
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone [no description available]	2.89	3	aromatic ketone; thienopyrimidine
pha 793887 [no description available]	2.89	3	piperidinecarboxamide
abt-348 ilorasertib: an antineoplastic agent and protein kinase inhibitor; structure in first source	2.06	1
gsk 2334470 GSK 2334470: a PDK1 inhibitor; structure in first source	2.21	1	indazoles
ml228 probe ML228 probe: structure in first source. ML228 : A member of the class of 1,2,4-triazines in which the triazine ring is substituted at positions 3, 5, and 6 by pyridin-2-yl, ([biphenyl]-4-ylmethyl)amin, and methyl groups, respectively. It is an activator of the hypoxia inducible factor (HIF) pathway.	2.89	3	1,2,4-triazines; biphenyls; pyridines; secondary amino compound	hypoxia-inducible factor pathway activator
pf-03882845 [no description available]	2.89	3
jq1 compound [no description available]	2.89	3	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
pf-04620110 PF-04620110: a DGAT1 inhibitor; structure in first source	2.89	3
gsk525762a molibresib: mimicks acetylated histones; structure in first source	2.89	3	benzodiazepine
birinapant birinapant: a Smac mimetic with antineoplastic activity	2.21	1	dipeptide
torin 1 torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	2.89	3	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	2.89	3	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea [no description available]	2.89	3	ureas
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide [no description available]	2.89	3	(trifluoromethyl)benzenes
ncgc00242364 NCGC00242364: structure in first source	2.89	3	quinazolines
gsk1210151a GSK1210151A: inhibitor of the BET family of proteins; structure in first source	2.89	3	imidazoquinoline
hs-173 [no description available]	2.89	3
sr1664 [no description available]	2.89	3	indolecarboxamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide 4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide: inhibits phosphopantetheinyl transferase; structure in first source	2.89	3
natriuretic peptide, brain Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.	2.44	2	polypeptide
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide [no description available]	2.59	2	benzamides; N-acylpiperidine
N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.59	2	aminoquinoline
heparitin sulfate Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.	2.03	1
cudc-907 [no description available]	2.89	3
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	2.03	1
methacycline Methacycline: A broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.. methacycline : A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.	2.21	1
lfm a13 LFM-A13 : An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties.	2.03	1	aromatic amide; dibromobenzene; enamide; enol; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 2.7.11.21 (polo kinase) inhibitor; geroprotector; platelet aggregation inhibitor
methacycline monohydrochloride [no description available]	2.59	2
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid [no description available]	2.89	3	quinolines
hispidin hispidin: metabolite of Basidiomycete Polyporus hispidus. hispidin : Fungal metabolite first found in basidiomycete Inonotus hispidus (formerly Polyporus hispidus).	2.72	3	2-pyranones; catechols	antioxidant; EC 2.7.11.13 (protein kinase C) inhibitor; fungal metabolite
agi-5198 AGI-5198: inhibits isocitrate dehydrogenase 1; structure in first source	2.89	3
snx 230 omega-conotoxin-MVIIC: isolated from Conus magus; amino acid sequence given in first source	2.02	1
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	3.81	11
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	3.89	12
cep-32496 agerafenib: inhibitor of RAF family kinases; structure in first source	2.89	3
saxitoxin Saxitoxin: A compound that contains a reduced purine ring system but is not biosynthetically related to the purine alkaloids. It is a poison found in certain edible mollusks at certain times; elaborated by GONYAULAX and consumed by mollusks, fishes, etc. without ill effects. It is neurotoxic and causes RESPIRATORY PARALYSIS and other effects in MAMMALS, known as paralytic SHELLFISH poisoning.. saxitoxin : An alkaloid isolated from the marine dinoflagellates and cyanobacteria that causes paralytic shellfish poisoning.	2.41	2	alkaloid; carbamate ester; guanidines; ketone hydrate; paralytic shellfish toxin; pyrrolopurine	cyanotoxin; marine metabolite; neurotoxin; sodium channel blocker; toxin
epz004777 [no description available]	2.89	3	N-glycosyl compound
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid [no description available]	2.89	3	organonitrogen heterocyclic compound
okadaic acid Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.	2.72	3	ketal
entecavir [no description available]	2.89	3	benzamides; N-acylpiperidine
gkt137831 setanaxib: NOX4/NOX1 inhibitor; a pyrazolopyridine dione derivative	2.89	3
vx-509 [no description available]	2.89	3
vx-970 berzosertib: an ATR kinase inhibitor	2.89	3	sulfonamide
gs-9973 [no description available]	2.89	3
amg 925 AMG-925 : An organic heterotricyclic compound that is 9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine which is substituted by a [6-(hydroxyacetyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]nitrilo group at position 2 and by a trans-4-methylcyclohexyl group at position 9. It is a FLT3 and CDK4 dual kinase inhibitor that has antineoplastic activity. Currently under clinical investigation in patients with relapsed or refractory acute myeloid leukemia (AML).	2.89	3
gne-618 GNE-618: inhibits nicotinamide phosphoribosyl transferase; structure in first source	2.89	3
g007-lk G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source	2.89	3
volitinib [no description available]	2.89	3
ML355 ML355: 12-Lipoxygenase inhibitor. ML355 : A sulfonamide resulting from the formal condensation of the amino group of 2-aminobenzothiazole with the sulfo group of 4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonic acid. It is an inhibitor of 12-lipoxygenase, being developed by Veralox Therapeutics for the treatment of heparin-induced thrombocytopenia and thrombosis.	2.89	3	benzothiazoles; monomethoxybenzene; phenols; secondary amino compound; substituted aniline; sulfonamide	EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; platelet aggregation inhibitor
acp-196 acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity. acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.	2.89	3	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gsk343 GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).	2.89	3	aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
agi-6780 AGI-6780: inhibits isocitrate dehydrogenases 1 and 2; structure in first source	2.89	3
khs101 KHS101: a small molecule accelerates neuronal differentiation in the adult rat	2.89	3
cb-839 [no description available]	2.89	3
gsk-j4 GSK-J4: a JMJD3 inhibitor; structure in first source	2.89	3	organonitrogen heterocyclic compound
pf-06424439 PF-06424439: an inhibitor of diacylglycerol acyltransferase 2; structure in first source	2.89	3
etp-46464 ETP-46464: inhibits ATM and Rad3-related kinase; structure in first source	2.89	3
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	3.12	5
onc201 TIC10 compound: a TRAIL-dependent antitumor agent; structure in first source	2.89	3
kai407 KAI407: an antimalarial; structure in first source	2.89	3
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source	2.89	3
oligomycins Oligomycins: A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X).	2.5	2
enasidenib [no description available]	2.89	3	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
calpastatin calpastatin: large mol wt, heat-stable calpain inhibitor; not based on sequestering Ca++ from medium, but binding to calpain does require Ca++. calpastatin peptide Ac 184-210 : A 27-membered polypeptide comprising the sequence Ac-Asp-Pro-Met-Ser-Ser-Thr-Tyr-Ile-Glu-Glu-Leu-Gly-Lys-Arg-Glu-Val-Thr-Ile-Pro-Pro-Lys-Tyr-Arg-Glu-Leu-Leu-Ala-NH2. An acetylated synthetic peptide from human calpastatin that strongly inhibits both calpains I and II but not papain (a cysteine protease) or trypsin (a serine protease).	2	1	polypeptide	EC 3.4.22.52 (calpain-1) inhibitor; EC 3.4.22.53 (calpain-2) inhibitor
oicr-9429 OICR-9429: antineoplastic; structure in first source	2.89	3
lly-507 LLY-507: inhibits methyltransferase SMYD2; structure in first source. LLY-507 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-cyano-2'-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}[biphenyl]-3-carboxylic acid with the amino group of 3-(pyrrolidin-1-yl)propan-1-amine. It is a potent and selective inhibitor of SMYD2 and inhibits the ability of SMYD2 to methylate p53. It serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.	2.89	3
aprinocarsen ISIS 3521: 20-nucleotide phosphorothioate antisense molecule that targets protein kinase C-alpha isoenzyme	3.1	1
transforming growth factor alpha Transforming Growth Factor alpha: An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.	2.02	1
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.03	1
cytochalasin d Cytochalasin D: A fungal metabolite that blocks cytoplasmic cleavage by blocking formation of contractile microfilament structures resulting in multinucleated cell formation, reversible inhibition of cell movement, and the induction of cellular extrusion. Additional reported effects include the inhibition of actin polymerization, DNA synthesis, sperm motility, glucose transport, thyroid secretion, and growth hormone release.. cytochalasin D : An organic heterotricyclic compound that is a mycotoxin produced by Helminthosporium and other moulds which is cell permeable and a potent inhibitor of actin polymerisation and DNA synthesis.	3.11	5
thromboplastin Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.	2.11	1
muramidase Muramidase: A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17.	1.98	1
at 9283 [no description available]	2.89	3
akt-i-1,2 compound Akt-I-1,2 compound: an aminopeptidase P inhibitor; structure in first source	2.46	2
chir 258 [no description available]	2.45	2
r 1530 [no description available]	2.48	2
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	2.06	1	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.47	2	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
hypoxanthine [no description available]	2.89	3	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite
guanosine 5'-o-(3-thiotriphosphate) Guanosine 5'-O-(3-Thiotriphosphate): Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.	2.01	1	nucleoside triphosphate analogue
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	3.03	4	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
ganciclovir [no description available]	2.41	2	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.03	1	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	2.03	1	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
vardenafil vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.	2.03	1	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
1-hydroxyphenazine 1-hydroxyphenazine: a virulence factor of Pseudomonas aeruginosa. 1-hydroxyphenazine : A phenazine carrying a hydroxy substituent at the 1-position.	2.89	3	phenazines
hymenialdisine [no description available]	2.03	1
isogranulatimide isogranulatimide: G2 checkpoint inhibitor; structure in first source	2.46	2
ro 24-7429 Ro 24-7429: blocks the action of the HIV tat protein; an analog of Ro 5-3335; Proc Natl Acad Sci U S A 1993 Jul 15;90(14):6395-9	3	4	benzodiazepine
nintedanib nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.	2.89	3
methylnitronitrosoguanidine Methylnitronitrosoguanidine: A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties.. N-methyl-N'-nitro-N-nitrosoguanidine : An N-nitroguanidine compound having nitroso and methyl substituents at the N'-position	2.04	1	nitroso compound	alkylating agent
6-bromoindirubin-3'-acetoxime 6-bromoindirubin-3'-acetoxime: a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, protects cells from varicella infection	2.08	1
debromohymenialdisine [no description available]	2.03	1
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide [no description available]	2.89	3	catechols; hydrazide; hydrazone; naphthols	EC 3.6.5.5 (dynamin GTPase) inhibitor
ver 52296 luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.	2.89	3	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile 2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile: structure in first source. AZD1080 : A member of the class of hydroxyindoles that is 1H-indole substituted by hydroxy, 5-(morpholin-4-ylmethyl)pyridin-2-yl, and cyano groups at positions 2, 3 and 5, respectively. It is a potent, brain permeable inhibitor of human GSK3alpha and GSK3beta with Ki of 6.9 nM and 31 nM, respectively. The drug was being developed by AstraZeneca for the treatment of Alzheimer's disease (clinical trial now discontinued).	2.06	1	hydroxyindoles; morpholines; nitrile; pyridines; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; tau aggregation inhibitor
rvx 208 apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation	2.89	3
bmn 673 talazoparib: inhibits both PARP1 and PARP2; structure in first source	2.89	3
crt 0066101 CRT 0066101: protein kinase D inhibitor with antineoplastic activity	2.06	1
lipoteichoic acid lipoteichoic acid: lipopolysaccharides with an acyl group anchored to the cell membrane of gram-positive bacteria; functions as an adhesion molecule to facilitate the binding of bacteria to cells, colonization, and invasion; interacts with CD14 to induce NF-κB activation and inflammatory cytokine production; can function as surface antigen; inhibits remineraliztion of artificial lesions and surface-softened enamels;. lipoteichoic acid : A teichoic acid which is covalently bound to a lipid.	2.01	1
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	2	1
filipin Filipin: A complex of polyene antibiotics obtained from Streptomyces filipinensis. Filipin III alters membrane function by interfering with membrane sterols, inhibits mitochondrial respiration, and is proposed as an antifungal agent. Filipins I, II, and IV are less important.	2.07	1

Condition	Relationship Strength	Studies	Trials
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.78	10	0
Autoimmune Demyelinating Diseases, Central Nervous System [description not available]	2.03	1	0
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	2.44	2	0
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	2.44	2	0
Encephalitis, Polio [description not available]	2.06	1	0
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1	0
Chickungunya Fever [description not available]	3.06	1	0
Congenital Zika Syndrome [description not available]	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	2.41	1	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	2.41	1	0
Cardiomyopathy, Congestive [description not available]	2.41	1	0
Cardiomyopathy, Dilated A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.	2.41	1	0
Adjuvant Arthritis [description not available]	2.21	1	0
Encephalopathy, Toxic [description not available]	2.25	1	0
Cirrhosis [description not available]	2.31	1	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.31	1	0
Granulocytic Leukemia, Chronic [description not available]	2.48	2	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	2.48	2	0
Arthritis, Degenerative [description not available]	2.45	2	0
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	2.45	2	0
Glial Cell Tumors [description not available]	2.72	3	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.72	3	0
Encephalopathy, Traumatic [description not available]	2.21	1	0
Brain Swelling [description not available]	2.21	1	0
Hypercapnia A clinical manifestation of abnormal increase in the amount of carbon dioxide in arterial blood.	2.21	1	0
Brain Injuries, Traumatic A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain.	2.21	1	0
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	2.21	1	0
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	3.64	9	0
Injuries, Spinal Cord [description not available]	2.1	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	3.28	6	0
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	2.1	1	0
Innate Inflammatory Response [description not available]	2.52	2	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.52	2	0
Invasiveness, Neoplasm [description not available]	3.27	6	0
Leucocythaemia [description not available]	2.43	2	0
Acute Disease Disease having a short and relatively severe course.	2.46	2	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.43	2	0
Inflammatory Response Syndrome, Systemic [description not available]	2.1	1	0
Systemic Inflammatory Response Syndrome A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever	2.1	1	0
Malignant Melanoma [description not available]	3.15	5	0
Benign Neoplasms [description not available]	2.74	3	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	3.15	5	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.74	3	0
Cancer of the Urinary Tract [description not available]	2.11	1	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	2.1	1	0
Breast Cancer [description not available]	3.73	10	0
Breast Neoplasms Tumors or cancer of the human BREAST.	3.73	10	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.1	1	0
Insulin Sensitivity [description not available]	2.44	2	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.1	1	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.44	2	0
Benign Neoplasms, Brain [description not available]	2.13	1	0
Astrocytoma, Grade IV [description not available]	2.13	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.13	1	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.13	1	0
Bladder Cancer [description not available]	3.14	5	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	3.14	5	0
Age-Related Memory Disorders [description not available]	2.11	1	0
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.11	1	0
Allodynia [description not available]	2.13	1	0
Encapsulating Peritoneal Sclerosis [description not available]	2.13	1	0
Cancer of Skin [description not available]	2.75	3	0
Skin Neoplasms Tumors or cancer of the SKIN.	2.75	3	0
Apoplexy [description not available]	2.45	2	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.45	2	0
Cancer of Ovary [description not available]	2.04	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.04	1	0
Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position.	2.04	1	0
Bile Duct Obstruction [description not available]	3.14	5	0
Cholestasis Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).	3.14	5	0
Cancer of Prostate [description not available]	2.44	2	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.44	2	0
Infections, Staphylococcal [description not available]	2.05	1	0
Chediak-Higashi Syndrome A form of phagocyte bactericidal dysfunction characterized by unusual oculocutaneous albinism, high incidence of lymphoreticular neoplasms, and recurrent pyogenic infections. In many cell types, abnormal lysosomes are present leading to defective pigment distribution and abnormal neutrophil functions. The disease is transmitted by autosomal recessive inheritance and a similar disorder occurs in the beige mouse, the Aleutian mink, and albino Hereford cattle.	2.05	1	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	2.05	1	0
Clinically Isolated CNS Demyelinating Syndrome [description not available]	2.05	1	0
Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.	2.05	1	0
Abnormalities, Autosome [description not available]	2.05	1	0
Cancer of Colon [description not available]	2.94	4	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.94	4	0
Anemia, Fanconi [description not available]	2.05	1	0
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.05	1	0
Acute Confusional Senile Dementia [description not available]	2.43	2	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.43	2	0
Ewing Sarcoma [description not available]	2.05	1	0
Sarcoma, Ewing A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.	2.05	1	0
Metastase [description not available]	2.95	4	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.95	4	0
Asthma, Bronchial [description not available]	2.05	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	2.05	1	0
Hemorrhagic Shock [description not available]	2.05	1	0
Cancer of Nasopharynx [description not available]	2.05	1	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	2.05	1	0
Cancer of Pancreas [description not available]	2.95	4	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.95	4	0
Acute Edematous Pancreatitis [description not available]	2.06	1	0
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	2.06	1	0
Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.	2.73	3	0
Acute Liver Injury, Drug-Induced [description not available]	2.06	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.06	1	0
Muscle Disorders [description not available]	2.06	1	0
Muscular Diseases Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.	2.06	1	0
Carcinoma, Epidermoid [description not available]	2.43	2	0
Cancer of Head [description not available]	2.06	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.43	2	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.06	1	0
Carcinoma, Oat Cell [description not available]	2.44	2	0
Cancer of Lung [description not available]	3.15	5	0
Lung Neoplasms Tumors or cancer of the LUNG.	3.15	5	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	2.44	2	0
Infections, Salmonella [description not available]	2.06	1	0
Carcinoma, Non-Small Cell Lung [description not available]	2.73	3	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.73	3	0
Diabetic Glomerulosclerosis [description not available]	2.07	1	0
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.07	1	0
Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL).	2.06	1	0
Chronic Hepatitis B [description not available]	2.06	1	0
Hepatocellular Carcinoma [description not available]	4.52	5	1
Cancer of Liver [description not available]	4.34	4	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	4.52	5	1
Liver Neoplasms Tumors or cancer of the LIVER.	4.34	4	1
Hepatitis B, Chronic INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	2.06	1	0
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	2.08	1	0
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	2.08	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	2.07	1	0
Adenocarcinoma, Basal Cell [description not available]	2.69	3	0
Experimental Mammary Neoplasms [description not available]	2.41	2	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.69	3	0
Chronic Lung Injury [description not available]	2.01	1	0
Anoxemia [description not available]	2.92	4	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.92	4	0
Allergic Contact Dermatitis [description not available]	2.01	1	0
Equine Diseases [description not available]	2.01	1	0
Dermatitis, Allergic Contact A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.	2.01	1	0
Angiogenesis, Pathologic [description not available]	2.02	1	0
Injury, Ischemia-Reperfusion [description not available]	2.43	2	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.43	2	0
Germinoblastoma [description not available]	2.02	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.02	1	0
Anaplastic Astrocytoma [description not available]	2.92	4	0
Astrocytoma Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)	2.92	4	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.41	2	0
Disease Exacerbation [description not available]	2.02	1	0
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	2.02	1	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	2.02	1	0
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	2.02	1	0
Bone Loss, Osteoclastic [description not available]	2.02	1	0
Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.	2.03	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.03	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.93	4	0
Alveolitis, Fibrosing [description not available]	2.03	1	0
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	2.03	1	0
Granulocytic Leukemia [description not available]	2.44	2	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2.44	2	0
Atherogenesis [description not available]	2.03	1	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.03	1	0
Labor, Premature [description not available]	2.03	1	0
Blood Poisoning [description not available]	2.03	1	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	2.03	1	0
Edema, Pulmonary [description not available]	2.03	1	0
Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.	2.03	1	0
Kahler Disease [description not available]	2.04	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	2.04	1	0
Benign Cerebellar Neoplasms [description not available]	2.03	1	0
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	2.03	1	0
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	2.03	1	0
Cardiac Failure [description not available]	2.04	1	0
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.04	1	0
EBV Infections [description not available]	2.04	1	0
Epstein-Barr Virus Infections Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).	2.04	1	0
Alloxan Diabetes [description not available]	2.04	1	0
Diabetes Mellitus, Adult-Onset [description not available]	2.04	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.04	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.04	1	0
Adenoma, beta-Cell [description not available]	1.99	1	0
Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.	1.99	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.4	2	0
Experimental Neoplasms [description not available]	1.99	1	0
Cancer of the Uterus [description not available]	1.99	1	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	1.99	1	0
Acute Lymphoid Leukemia [description not available]	2	1	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2	1	0
Cancer of Rectum [description not available]	2	1	0
Rectal Neoplasms Tumors or cancer of the RECTUM.	2	1	0
Acute Promyelocytic Leukemia [description not available]	2	1	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	2	1	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	2	1	0
Cytomegalic Inclusion Disease [description not available]	2	1	0
Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.	2	1	0
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	2.41	2	0
Rheumatoid Arthritis [description not available]	2	1	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2	1	0
Heart Disease, Ischemic [description not available]	2	1	0
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	2	1	0
Angiospasm, Intracranial [description not available]	2	1	0
Vasospasm, Intracranial Constriction of arteries in the SKULL due to sudden, sharp, and often persistent smooth muscle contraction in blood vessels. Intracranial vasospasm results in reduced vessel lumen caliber, restricted blood flow to the brain, and BRAIN ISCHEMIA that may lead to hypoxic-ischemic brain injury (HYPOXIA-ISCHEMIA, BRAIN).	2	1	0
Cancer of Pituitary [description not available]	2	1	0
Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.	2	1	0
Cancer of Cervix [description not available]	2	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2	1	0
Inflammation, Endodontic [description not available]	2	1	0
Pulpitis Inflammation of the DENTAL PULP, usually due to bacterial infection in dental caries, tooth fracture, or other conditions causing exposure of the pulp to bacterial invasion. Chemical irritants, thermal factors, hyperemic changes, and other factors may also cause pulpitis.	2	1	0
Plasma Cell Tumor [description not available]	2.01	1	0
Plasmacytoma Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.	2.01	1	0

go 6976

Cross-References

Synonyms (80)

Research Excerpts

Toxicity

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (2)

Protein Targets (20)

Potency Measurements

Inhibition Measurements

Biological Processes (289)

Molecular Functions (54)

Ceullar Components (69)

Bioassays (644)

Research

Studies (496)

Market Indicators

Research Demand Index: 27.05

Study Types

go 6976

Cross-References

Synonyms (80)

Research Excerpts

Toxicity

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (2)

Protein Targets (20)

Potency Measurements

Inhibition Measurements

Biological Processes (289)

Molecular Functions (54)

Ceullar Components (69)

Bioassays (644)

Research

Studies (496)

Market Indicators

Research Demand Index: 27.05

Study Types

Related Drugs (1,016)

Related Conditions (205)